<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-9-181</article-id><article-id pub-id-type="pmid">19523210</article-id><article-id pub-id-type="doi">10.1186/1471-2407-9-181</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Variations in the <italic>NBN/NBS1 </italic>gene and the risk of breast cancer in non-<italic>BRCA1/2 </italic>French Canadian families with high risk of breast cancer</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Desjardins</surname><given-names>Sylvie</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>sylvie.desjardins@crchul.ulaval.ca</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Beauparlant</surname><given-names>Joly Charles</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>charles.joly-beauparlant@crchul.ulaval.ca</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Labrie</surname><given-names>Yvan</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>yvan.labrie@crchul.ulaval.ca</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Ouellette</surname><given-names>Genevi&#x000e8;ve</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>genevieve.ouellette@crchul.ulaval.ca</email></contrib><contrib id="A5" contrib-type="author"><collab>INHERIT BRCAs</collab><xref ref-type="aff" rid="I1">1</xref><email>jacques.simard@crchul.ulaval.ca</email></contrib><contrib id="A6" corresp="yes" contrib-type="author"><name><surname>Durocher</surname><given-names>Francine</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>francine.durocher@crchul.ulaval.ca</email></contrib></contrib-group><aff id="I1"><label>1</label>Cancer Genomics Laboratory, Oncology and Molecular Endocrinology Research Centre, Centre Hospitalier Universitaire de Qu&#x000e9;bec and Laval University, Qu&#x000e9;bec, Canada</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>12</day><month>6</month><year>2009</year></pub-date><volume>9</volume><fpage>181</fpage><lpage>181</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/9/181"/><history><date date-type="received"><day>21</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>12</day><month>6</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Desjardins et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Desjardins et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Desjardins Sylvie sylvie.desjardins@crchul.ulaval.ca </dc:author><dc:title> Variations in the NBN/NBS1 gene and the risk of breast cancer in non-BRCA1/2 French Canadian families with high risk of breast cancer </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>BMC Cancer 9(1): 181-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2407(2009)9:1&#x0003c;181&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2407</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The Nijmegen Breakage Syndrome is a chromosomal instability disorder characterized by microcephaly, growth retardation, immunodeficiency, and increased frequency of cancers. Familial studies on relatives of these patients indicated that they also appear to be at increased risk of cancer.</p></sec><sec sec-type="methods"><title>Methods</title><p>In a candidate gene study aiming at identifying genetic determinants of breast cancer susceptibility, we undertook the full sequencing of the <italic>NBN </italic>gene in our cohort of 97 high-risk non-<italic>BRCA1 </italic>and -<italic>BRCA2 </italic>breast cancer families, along with 74 healthy unrelated controls, also from the French Canadian population. <italic>In silico </italic>programs (ESEfinder, NNSplice, Splice Site Finder and MatInspector) were used to assess the putative impact of the variants identified. The effect of the promoter variant was further studied by luciferase gene reporter assay in MCF-7, HEK293, HeLa and LNCaP cell lines.</p></sec><sec><title>Results</title><p>Twenty-four variants were identified in our case series and their frequency was further evaluated in healthy controls. The potentially deleterious p.Ile171Val variant was observed in one case only. The p.Arg215Trp variant, suggested to impair NBN binding to histone &#x003b3;-H2AX, was observed in one breast cancer case and one healthy control. A promoter variant c.-242-110delAGTA displayed a significant variation in frequency between both sample sets. Luciferase reporter gene assay of the promoter construct bearing this variant did not suggest a variation of expression in the MCF-7 breast cancer cell line, but indicated a reduction of luciferase expression in both the HEK293 and LNCaP cell lines.</p></sec><sec><title>Conclusion</title><p>Our analysis of <italic>NBN </italic>sequence variations indicated that potential <italic>NBN </italic>alterations are present, albeit at a low frequency, in our cohort of high-risk breast cancer cases. Further analyses will be needed to fully ascertain the exact impact of those variants on breast cancer susceptibility, in particular for variants located in <italic>NBN </italic>promoter region.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Pathogenic mutations in <italic>BRCA1</italic>, <italic>BRCA2</italic>, <italic>TP53</italic>, <italic>ATM</italic>, <italic>CHEK2</italic>, <italic>BRIP1 </italic>and <italic>PALB2 </italic>have been associated with an increased breast cancer risk and, together, are found in less than 25% of breast cancer families showing a clear pattern of inheritance (high-risk families) [<xref ref-type="bibr" rid="B1">1</xref>]. It is thus clear that other susceptibility alleles remain to be identified to explain the increased risk in the remnant high-risk families. As the number and characteristics of such alleles are undetermined, a focussed candidate gene approach based on genes closely interacting with the known susceptibility genes such as <italic>BRCA1 </italic>and <italic>BRCA2</italic>, the two major susceptibility genes identified yet, constitutes a study design of choice to identify rare-moderate-penetrance susceptibility alleles.</p><p>In the cell, nibrin, encoded by the <italic>NBN </italic>gene (also known as <italic>NBS1</italic>), participates in pathways of double strand breaks (DSB)-induced DNA repair and, together with its partners MRE11A and RAD50, is required for activation of these pathways in response to DNA damages [<xref ref-type="bibr" rid="B2">2</xref>]. In fact, nibrin is at the crossroad of several pathways implicating genes already associated with breast cancer susceptibility and/or chromosomal instability disorders [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. Individuals homozygous for hypomorphic mutations in <italic>NBN </italic>suffer from the Nijmegen Breakage Syndrome (NBS), an autosomal recessive chromosomal instability disorder characterized by microcephaly, growth retardation, immunodeficiency and hyper-radiosensitivity [<xref ref-type="bibr" rid="B4">4</xref>]. Cancers, in particular haematological malignancies, are common adverse events in patients with NBS, as almost 40% of them develop a malignancy before the age of 21 years, and this correlates with a marked impairment in DSB repair observed in cells from these patients [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>Some studies have associated an heterozygous <italic>NBN </italic>status with numerous types of cancers, including breast cancer [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B10">10</xref>], suggesting that being a carrier of a deleterious mutation in <italic>NBN </italic>may confer an increased risk of approximately 2 to 3-fold [<xref ref-type="bibr" rid="B6">6</xref>]. This was also supported by the observation that relatives of NBS patients display a higher than expected rate of cancers [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. However, other studies failed to find an association with an increased risk of cancer [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>].</p><p>In support of a role of <italic>NBN </italic>in tumor formation, evidence from mouse models demonstrated that <italic>Nbn </italic>heterozygosity predisposes cells to malignancies, as they display a wide variety of tumors: liver, mammary gland, prostate, lung as well as lymphomas [<xref ref-type="bibr" rid="B14">14</xref>]. Indeed, cells from these mice displayed an elevated frequency of chromosomal aberrations. These observations were correlated by studies of <italic>NBN </italic>heterozygous mutation carriers demonstrating that cell lines from these individuals showed spontaneous chromosomal instability (chromatid and chromosomes breaks, and chromosomes rearrangements) [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>] as well as increased sensitivity to radiation-induced chromosomal aberrations [<xref ref-type="bibr" rid="B17">17</xref>]. Thus, it has been hypothesized that in cells of carriers of deleterious mutations in DNA repair genes such as <italic>NBN</italic>, a decrease in DNA repair capabilities resulting from a gene dosage effect (i.e. lower gene expression) may be sufficient to create a permissive environment for tumor development [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. It has also been suggested that these DNA repair genes may show differences in tissue-specific protein-dosage thresholds, below which they may fail to operate normally [<xref ref-type="bibr" rid="B20">20</xref>].</p><p>Thus, based on the close relation of <italic>NBN </italic>and known breast cancer susceptibility genes in the cell DNA repair pathways, and the studies suggesting a possible involvement of <italic>NBN </italic>alterations in cancer susceptibility, we undertook the analysis of the entire coding sequence, intron/exon junctions, as well as the proximal promoter region of the <italic>NBN </italic>gene. We therefore performed a thorough re-sequencing of a series of 97 breast cancer cases selected from high-risk families from the French Canadian population, and 74 unrelated healthy controls from the same origin for sequence variations that could possibly modulate breast cancer risk.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Ascertainment of families</title><p>All 97 non-<italic>BRCA1/2 </italic>individuals from high-risk French Canadian breast and ovarian cancer families participating in this study were part of a larger interdisciplinary program termed INHERIT BRCAs [<xref ref-type="bibr" rid="B21">21</xref>]. All participants were at least 18 years of age and had to sign an informed consent form. Ethics committees reviewed the research project at the 7 participating institutions from which the patients were referred. The details regarding selection criteria of the breast cancer cases as well as the experimental and clinical procedures have been described previously [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>].</p></sec><sec><title>PCR amplification and direct sequencing</title><p>PCR amplification of <italic>NBN </italic>(NM_002485.4) coding sequence, as well as flanking intronic regions, was performed on breast cancer cases and controls using primer pairs as described in Table <xref ref-type="table" rid="T1">1</xref>. Sequencing reactions and sequence analysis were performed as described previously [<xref ref-type="bibr" rid="B22">22</xref>]. Alternative splice screening was also performed on cDNA on a subset of breast cancer cases using primers as described in Table <xref ref-type="table" rid="T1">1</xref>.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Oligonucleotides used for <italic>NBN </italic>PCR amplification and sequencing.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center">F/R<sup>1</sup></td><td align="center">Oligonucleotide sequence (5'&#x02192;3')</td><td align="center">Annealing temp. (&#x000b0;C)</td><td align="center">PCR lenght (bp)</td><td align="center">MgCl<sub>2 </sub>final conc. (mM)</td><td align="center">Comments</td></tr></thead><tbody><tr><td align="left" colspan="7">Genomic sequence</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">Exon 1</td><td align="center">F</td><td align="left">GACGTTAAGACAAGTTGATTTGAACTTAGA*</td><td align="center">60</td><td align="center">965/</td><td align="center">0.5</td><td align="left">2% DMSO added to the PCR reaction</td></tr><tr><td></td><td align="center">R</td><td align="left">TCCGCCCATGCTAACTTCCT</td><td></td><td align="center">1113</td><td></td><td></td></tr><tr><td></td><td align="center">F<sup>2</sup></td><td align="left">TTTAGTAGTGCGCAGGATGTAGAC</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">Exon 2</td><td align="center">F</td><td align="left">CCTTTGATAGCCTTCAGTGAGGC</td><td align="center">64</td><td align="center">743</td><td align="center">1.0</td><td align="left">Sequencing primer:</td></tr><tr><td></td><td align="center">R</td><td align="left">AGCCAGAGTCATGAAGGTCTGTTC</td><td></td><td></td><td></td><td align="left">CCACTGGTACCACTGCCACA</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">Exon 3</td><td align="center">F</td><td align="left">GTCAGGAGAATCCCCACTGACTT*</td><td align="center">60</td><td align="center">548</td><td align="center">1.5</td><td></td></tr><tr><td></td><td align="center">R</td><td align="left">GGCACAGAGTCCAATACTGTGCT</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">Exon 4</td><td align="center">F</td><td align="left">TGGGAAGTTACATTTCTTCGATTCC*</td><td align="center">58</td><td align="center">728</td><td align="center">1.5</td><td></td></tr><tr><td></td><td align="center">R</td><td align="left">GCACTGTCATAACCTTCTCGGTG</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">Exon 5</td><td align="center">F</td><td align="left">GCAGTGACCAAAGACCGACTTCTA*</td><td align="center">58</td><td align="center">561</td><td align="center">1.5</td><td></td></tr><tr><td></td><td align="center">R</td><td align="left">TGAGGTTACCTCAGTGCCATTTACT*</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">Exon 6</td><td align="center">F</td><td align="left">AAACGCGATTAGATGCTTTTTGTC*</td><td align="center">60</td><td align="center">630</td><td align="center">1.5</td><td></td></tr><tr><td></td><td align="center">R</td><td align="left">ACCCCACTTTGGTACACAGAAC</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">Exon 7</td><td align="center">F</td><td align="left">CCACAGAGAGTGTAACAGTTCCAGG*</td><td align="center">63</td><td align="center">1100</td><td align="center">1.0</td><td align="left">2% DMSO added to the PCR reaction</td></tr><tr><td></td><td align="center">R</td><td align="left">TTAATTCTTGTATCGGCCGGG</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">Exon 8</td><td align="center">F</td><td align="left">TAACAGTGCCCCAGCGAGTAAG*</td><td align="center">58</td><td align="center">785</td><td align="center">1.5</td><td></td></tr><tr><td></td><td align="center">R</td><td align="left">TCCTCTTACACTGTCGACCCTTAGA</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">Exon 9</td><td align="center">F</td><td align="left">TTAGATAAGCCCGTCATAGATGCC*</td><td align="center">58</td><td align="center">516</td><td align="center">1.5</td><td></td></tr><tr><td></td><td align="center">R</td><td align="left">TAACTACTCGCCGCTCCTTTACA</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">Exon 10</td><td align="center">F</td><td align="left">GTTTGTCAGTCGTCTATAGTGGAGCA*</td><td align="center">58</td><td align="center">763</td><td align="center">1.5</td><td></td></tr><tr><td></td><td align="center">R</td><td align="left">AATTGCGGCAAGTAAAATAACACG</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">Exon 11</td><td align="center">F</td><td align="left">CCCTGCCCACAACCTTACTACG*</td><td align="center">60</td><td align="center">1500</td><td align="center">1.5</td><td></td></tr><tr><td></td><td align="center">R</td><td align="left">GACCACAGCCATGAATGAGTGG *</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">Exon 12</td><td align="center">F</td><td align="left">TCCTACCATCTACAGACAACCATGG</td><td align="center">58</td><td align="center">619</td><td align="center">1.5</td><td></td></tr><tr><td></td><td align="center">R</td><td align="left">CCATGATCAATCCATTTCAAGGC *</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">Exon 13</td><td align="center">F</td><td align="left">GCAAACAGTGCTGAGATTTTGTGTC</td><td align="center">58</td><td align="center">850</td><td align="center">1.5</td><td></td></tr><tr><td></td><td align="center">R</td><td align="left">CCTGAGCTAAAGAACCTCCTCAAGTAG *</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">Exon 14</td><td align="center">F</td><td align="left">CAACATCTCCTGCTTGGACTCTG</td><td align="center">60</td><td align="center">638</td><td align="center">1.0</td><td align="left">Sequencing primer:</td></tr><tr><td></td><td align="center">R</td><td align="left">GAAGAATTTGCTTGAAGGCCACC</td><td></td><td></td><td></td><td align="left">GATGGGTTTAGAACAGAGTTACTGCT</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">Exon 15</td><td align="center">F</td><td align="left">GAACTCAGATGTGGTGACCTCCAG</td><td align="center">58</td><td align="center">441</td><td align="center">1.5</td><td></td></tr><tr><td></td><td align="center">R</td><td align="left">CAATTTCACACAATTCGGGAACC *</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">Exon 16</td><td align="center">F</td><td align="left">GAGGAATGGGGATCTTTGAAGC</td><td align="center">58</td><td align="center">457</td><td align="center">1.5</td><td align="left">Sequencing primer:</td></tr><tr><td></td><td align="center">R</td><td align="left">GTAACTTAAATCGCTTCTATACAC</td><td></td><td></td><td></td><td align="left">AAGCAACATCAAAGGGATACATGA</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left" colspan="7">cDNA</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">PCR 1</td><td align="center">F</td><td align="left">GTTACGCGGTTGCACGTCG</td><td align="center">64</td><td align="center">998</td><td align="center">1.5</td><td align="left">Exons 1 to 8</td></tr><tr><td></td><td align="center">R</td><td align="left">GTCATGAAAATCACCGCCAATC</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">PCR 2</td><td align="center">F</td><td align="left">TCTTTTTGGCTCCGGGAACG</td><td align="center">62</td><td align="center">567</td><td align="center">1.5</td><td align="left">Exons 7 to 10</td></tr><tr><td></td><td align="center">R</td><td align="left">GCTGCTGCTGAGAAGCCCTATC</td><td></td><td></td><td></td><td align="left">Overlap of 169 pb with PCR1</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">PCR 3</td><td align="center">F</td><td align="left">CCCACTGTAAAGGAGTCCTGCA</td><td align="center">62</td><td align="center">634</td><td align="center">1.5</td><td align="left">Exons 10 to 12</td></tr><tr><td></td><td align="center">R</td><td align="left">TACTTTCTGGTACTGCTTCATCACT</td><td></td><td></td><td></td><td align="left">Overlap of 151 pb with PCR2</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">PCR 4</td><td align="center">F</td><td align="left">CCATAGAAGATGAAGTATTGGA</td><td align="center">62</td><td align="center">700</td><td align="center">1.5</td><td align="left">Exons 11 to 16</td></tr><tr><td></td><td align="center">R</td><td align="left">GTAACTTAAATCGCTTCTATACAC</td><td></td><td></td><td></td><td align="left">Overlap of 165 pb with PCR3</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left" colspan="7">Promoter cloning</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td></td><td align="center">F</td><td align="left">GACGAC<underline>GCTAGC</underline>GACGTTAAGACAAGTTGATTTGAACTTAGA</td><td align="center">62</td><td align="center">515</td><td align="center">1.0</td><td align="left">2% DMSO added to the PCR reaction<break/>Added restriction sites are underlined</td></tr><tr><td></td><td align="center">R</td><td align="left">GACGAC<underline>AAGCTT</underline>ATCGGTCCGGCTCCTCAGGGCTG</td><td></td><td></td><td></td><td></td></tr></tbody></table><table-wrap-foot><p><sup>1 </sup>Primer direction: forward (F) or reverse (R) <sup>2 </sup>Alternative primer Oligonucleotides used as sequencing primers are marked with an (*)</p></table-wrap-foot></table-wrap></sec><sec><title>Variants characterization and haplotype estimations</title><p>Deviation from Hardy-Weinberg equilibrium (HWE) and allelic difference between both series was evaluated using a two-sided Chi Square test with 1 degree of freedom. The possible effect of a given variant on exonic splicing enhancers was assessed using the ESEfinder 3.0 program [<xref ref-type="bibr" rid="B23">23</xref>] and on splice consensus sites using NNSPLICE [<xref ref-type="bibr" rid="B24">24</xref>] and Splice Site Finder [<xref ref-type="bibr" rid="B25">25</xref>] web based programs. The potential impact of the promoter variant and pairwise linkage disequilibrium were evaluated as described elsewhere [<xref ref-type="bibr" rid="B26">26</xref>]. Haplotype analysis was performed using the WHAP program [<xref ref-type="bibr" rid="B27">27</xref>] implementing a regression-based association test allowing for evaluation of haplotype-specific association. Haplotype analyses were performed on all variants identified as well as on variants showing a minor allele frequency (MAF) greater than 5%.</p></sec><sec><title>Luciferase promoter assays</title><p>A portion of 401 bp of the <italic>NBN </italic>promoter region, and the entire 5'UTR sequence (110 bp), was amplified by PCR from a breast cancer individual carrier of the c.-242-110delAGTA deletion using primers introducing a <italic>NheI </italic>or a <italic>HindIII </italic>restriction site (Table <xref ref-type="table" rid="T1">1</xref>). PCR products were then digested and introduced in the pGL3 basic vector (Promega Corporation, Madison, WI, USA). Direct sequencing of clones was performed to confirm the presence of the reference sequence allele as well as the four nucleotides deletion. Transient transfections in MCF-7, LNCaP, HeLa and HEK293 cells and dual luciferase reporter assays were performed as described previously [<xref ref-type="bibr" rid="B26">26</xref>], with cells harvested 24&#x02013;48 h after transfection. <italic>ATBF1 </italic>expression levels were measured in these four cell lines by quantitative real-time PCR (QRT-PCR) as described previously [<xref ref-type="bibr" rid="B28">28</xref>], using RNA extracted by the TriReagent method (Molecular Research Center Inc, Cincinnati, OH, USA) and specific primers (sens: 5'-TGCAACTAAACCGCCCACATATA-3'; antisens 5'-CCCCAAGTGAGATAAAGCTAAACAAA-3'). Levels of expression were normalized using the housekeeping gene <italic>HPRT1</italic>, and are indicated relative to the MCF-7 cell line (sens primer: 5'-AGTTCTGTGGCCATCTGCTTAGTAG-3'; antisens primer: 5'-AAACAACAATCCGCCCAAAGG-3').</p></sec></sec><sec><title>Results</title><sec><title>Sequence variations in the NBN gene</title><p>Direct sequencing of <italic>NBN </italic>entire coding region, adjacent intronic sequences as well as the proximal promoter region was performed on 97 affected individuals from French Canadian breast and ovarian cancer families (one individual per family). Twenty-four variants were identified (Tables <xref ref-type="table" rid="T2">2</xref>, <xref ref-type="table" rid="T3">3</xref> and Figure <xref ref-type="fig" rid="F1">1</xref>), including a new rare synonymous change at codon 127 (c.381T/C) and a new variant located in intron 15 (c.2234+86T/G), both not reported in the literature and databases, and found exclusively among breast cancer cases. Variants identified in the case dataset were also genotyped in 74 healthy individuals from the same population. All SNPs genotyped were in HWE. Nine out of the 24 variations were located in the coding region (Table <xref ref-type="table" rid="T2">2</xref>), while the remaining 15 were located in untranslated regions (Table <xref ref-type="table" rid="T3">3</xref>). Among all variants identified, half (12) were considered as common (MAF &#x02265; 5%) while the remaining 12 were rare variations. Two rare non-synonymous exonic variants (c.511A/G and c.797C/T) were observed only once in the case series, of which p.Ile171Val is located in the first BRCA1 C-terminal (BRCT) domain (Figure <xref ref-type="fig" rid="F1">1</xref>). Of these two variants, only c.511A/G could be genotyped in an additional family member, i.e. an unaffected male cousin, who was found non-carrier (data not shown). Two other rare variants, c.283G/A and c.643C/T, were both observed in one breast cancer case and one control. For the c.643C/T variant, a DNA sample from another available family member affected with ovarian cancer was analyzed and turned out to be wild type (data not shown). Among the variants located in untranslated regions (Table <xref ref-type="table" rid="T3">3</xref>), the c.2234+86T/G variant was present exclusively in two breast cancer cases. When genotype frequencies of all variants were compared between both series, only the c.-242-110delAGTA variant in the promoter showed a statistically significant association with breast cancer (OR 3.4, 95% CI: 1.1&#x02013;10.5; p = 0.029).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Exonic sequence variations of the NBN gene in French Canadian breast cancer cases and healthy controls.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">SNP</td><td align="center">SNP ID<sup>1 </sup>(dbSNP ID)</td><td align="center">Protein change</td><td align="center">Location</td><td align="center">Series (No.)</td><td align="center">MAF<sup>2</sup></td><td align="center">Common homozygote No. (expected)<sup>3</sup></td><td align="center">Heterozygote No. (expected)<sup>3</sup></td><td align="center">Rare homozygote No. (expected)<sup>3</sup></td><td align="center">HWE p-value</td><td align="center">OR (95% CI)<sup>4</sup></td><td align="center">Reported MAF in Caucasian</td></tr></thead><tbody><tr><td align="center">1</td><td align="center">c.102G/A</td><td align="center">p.Leu34Leu</td><td align="center">Exon 2</td><td align="center">Cases (97)</td><td align="center">0.284</td><td align="center">52 (49.80)</td><td align="center">35 (39.41)</td><td align="center">10 (7.80)</td><td align="center">0.27</td><td align="center">0.7</td><td align="center">0.283&#x02013;0.450<sup>5</sup></td></tr><tr><td></td><td align="center">(rs1063045)</td><td></td><td></td><td align="center">Controls (71)</td><td align="center">0.310</td><td align="center">33 (33.82)</td><td align="center">32 (30.37)</td><td align="center">6 (6.82)</td><td align="center">0.65</td><td align="center">(0.4&#x02013;1.3)</td><td></td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="center">2</td><td align="center">c.283G/A</td><td align="center">p.Asp95Asn</td><td align="center">Exon 3</td><td align="center">Cases (97)</td><td align="center">0.005</td><td align="center">96 (96.00)</td><td align="center">1 (0.99)</td><td align="center">0 (0)</td><td align="center">0.96</td><td align="center">0.7</td><td></td></tr><tr><td></td><td align="center">(NA)<sup>6</sup></td><td></td><td></td><td align="center">Controls (71)</td><td align="center">0.007</td><td align="center">70 (70.00)</td><td align="center">1 (0.99)</td><td align="center">0 (0)</td><td align="center">0.95</td><td align="center">(0.0&#x02013;11.9)</td><td></td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="center">3</td><td align="center">c.381T/C</td><td align="center">p.Ala127Ala</td><td align="center">Exon 4</td><td align="center">Cases (97)</td><td align="center">0.005</td><td align="center">96 (96.00)</td><td align="center">1 (0.99)</td><td align="center">0 (0)</td><td align="center">0.96</td><td align="center">2.3</td><td></td></tr><tr><td></td><td align="center">(NA)</td><td></td><td></td><td align="center">Controls (72)</td><td align="center">0.000</td><td align="center">72 (72.00)</td><td align="center">0 (0)</td><td align="center">0 (0)</td><td align="center">1.00</td><td align="center">(0.1&#x02013;56.1)</td><td></td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="center">4</td><td align="center">c.511A/G</td><td align="center">p.Ile171Val</td><td align="center">Exon 5</td><td align="center">Cases (97)</td><td align="center">0.005</td><td align="center">96 (96.00)</td><td align="center">1 (0.99)</td><td align="center">0 (0)</td><td align="center">0.96</td><td align="center">2.3</td><td></td></tr><tr><td></td><td align="center">(NA)<sup>6</sup></td><td></td><td></td><td align="center">Controls (73)</td><td align="center">0.000</td><td align="center">73 (73.00)</td><td align="center">0 (0)</td><td align="center">0 (0)</td><td align="center">1.00</td><td align="center">(0.1&#x02013;57.0)</td><td></td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="center">5</td><td align="center">c.553G/C</td><td align="center">p.Glu185Gln</td><td align="center">Exon 5</td><td align="center">Cases (97)</td><td align="center">0.268</td><td align="center">54 (51.97)</td><td align="center">34 (38.06)</td><td align="center">9 (6.97)</td><td align="center">0.29</td><td align="center">0.6</td><td></td></tr><tr><td></td><td align="center">(rs1805794)</td><td></td><td></td><td align="center">Controls (73)</td><td align="center">0.308</td><td align="center">34 (34.93)</td><td align="center">33 (31.13)</td><td align="center">6 (6.93)</td><td align="center">0.61</td><td align="center">(0.3&#x02013;1.2)</td><td></td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="center">6</td><td align="center">c.643C/T</td><td align="center">p.Arg215Trp</td><td align="center">Exon 6</td><td align="center">Cases (97)</td><td align="center">0.005</td><td align="center">96 (96.00)</td><td align="center">1 (0.99)</td><td align="center">0 (0)</td><td align="center">0.96</td><td align="center">0.8</td><td></td></tr><tr><td></td><td align="center">(rs34767364)</td><td></td><td></td><td align="center">Controls (73)</td><td align="center">0.007</td><td align="center">72 (72.00)</td><td align="center">1 (0.99)</td><td align="center">0 (0)</td><td align="center">0.95</td><td align="center">(0.0&#x02013;12.2)</td><td></td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="center">7</td><td align="center">c.797C/T</td><td align="center">p.Pro266Leu</td><td align="center">Exon 7</td><td align="center">Cases (97)</td><td align="center">0.005</td><td align="center">96 (96.00)</td><td align="center">1 (0.99)</td><td align="center">0 (0)</td><td align="center">0.96</td><td align="center">2.3</td><td align="center">0.000<sup>5</sup></td></tr><tr><td></td><td align="center">(rs769420)</td><td></td><td></td><td align="center">Controls (73)</td><td align="center">0.000</td><td align="center">73 (73.00)</td><td align="center">0 (0)</td><td align="center">0 (0)</td><td align="center">1.00</td><td align="center">(0.1&#x02013;57.0)</td><td></td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="center">8</td><td align="center">c.1197T/C</td><td align="center">p.Asp399Asp</td><td align="center">Exon 10</td><td align="center">Cases (97)</td><td align="center">0.320</td><td align="center">47 (44.91)</td><td align="center">38 (42.19)</td><td align="center">12 (9.91)</td><td align="center">0.33</td><td align="center">0.9</td><td align="center">0.28&#x02013;0.45<sup>5</sup></td></tr><tr><td></td><td align="center">(rs709816)</td><td></td><td></td><td align="center">Controls (72)</td><td align="center">0.313</td><td align="center">34 (34.03)</td><td align="center">31 (30.94)</td><td align="center">7 (7.03)</td><td align="center">0.99</td><td align="center">(0.5&#x02013;1.7)</td><td></td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="center">9</td><td align="center">c.2016A/G</td><td align="center">p.Pro672Pro</td><td align="center">Exon 13</td><td align="center">Cases (97)</td><td align="center">0.284</td><td align="center">52 (49.80)</td><td align="center">35 (39.41)</td><td align="center">10 (7.80)</td><td align="center">0.27</td><td align="center">0.8</td><td align="center">0.283<sup>5</sup></td></tr><tr><td></td><td align="center">(rs1061302)</td><td></td><td></td><td align="center">Controls (70)</td><td align="center">0.300</td><td align="center">34 (34.30)</td><td align="center">30 (29.40)</td><td align="center">6 (6.30)</td><td align="center">0.86</td><td align="center">(0.4&#x02013;2.2)</td><td></td></tr></tbody></table><table-wrap-foot><p><sup>1 </sup>According to the nomenclature guidelines of the Human Genome Variation Society (reference sequence NM_002485.4), nucleotide number one being the A from the ATG codon.</p><p><sup>2 </sup>Minor allele frequency</p><p><sup>3 </sup>As expected under Hardy-Weinberg equilibrium</p><p><sup>4 </sup>Odds ratios for comparison of heterozygotes versus common homozygotes</p><p><sup>5 </sup>From NCBI dbSNP data.</p><p><sup>6 </sup>No entry in NCBI dbSNP database, although reported in the literature.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Promoter and intronic sequence variations of the NBN gene in French Canadian breast cancer cases and healthy controls.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">SNP</td><td align="center">SNP ID<sup>1</sup><break/>(dbSNP ID)</td><td align="center">Location</td><td align="center">Series (No.)</td><td align="center">MAF<sup>2</sup></td><td align="center">Common homozygote No. (expected)<sup>3</sup></td><td align="center">Heterozygote No. (expected)<sup>3</sup></td><td align="center">Rare homozygote No. (expected)<sup>3</sup></td><td align="center">HWE p-value</td><td align="center">OR (95% CI)<sup>4</sup></td><td align="center">Reported MAF in Caucasian</td></tr></thead><tbody><tr><td align="center">10</td><td align="center">c.-110-242delAGTA</td><td align="center">Promoter</td><td align="center">Cases (97)</td><td align="center">0.082</td><td align="center">81 (81.66)</td><td align="center">16 (14.68)</td><td align="center">0 (0.66)</td><td align="center">0.38</td><td align="center">3.4</td><td></td></tr><tr><td></td><td align="center">(rs36226237)</td><td></td><td align="center">Controls (72)</td><td align="center">0.028</td><td align="center">68 (68.06)</td><td align="center">4 (3.89)</td><td align="center">0 (0.06)</td><td align="center">0.81</td><td align="center">(1.1&#x02013;10.5)</td><td></td></tr><tr><td colspan="11"><hr></hr></td></tr><tr><td align="center">11</td><td align="center">c.702+149T/C</td><td align="center">Intron 6</td><td align="center">Cases (97)</td><td align="center">0.082</td><td align="center">83 (81.66)</td><td align="center">12 (14.68)</td><td align="center">2 (0.66)</td><td align="center">0.07</td><td align="center">0.7</td><td align="center">0.108&#x02013;0.117<sup>5</sup></td></tr><tr><td></td><td align="center">(rs3026271)</td><td></td><td align="center">Controls (73)</td><td align="center">0.089</td><td align="center">60 (60.58)</td><td align="center">13 (11.84)</td><td align="center">0 (0.58)</td><td align="center">0.40</td><td align="center">(0.3&#x02013;1.6)</td><td></td></tr><tr><td colspan="11"><hr></hr></td></tr><tr><td align="center">12</td><td align="center">c.703-29C/T</td><td align="center">Intron 6</td><td align="center">Cases (97)</td><td align="center">0.015</td><td align="center">94 (94.02)</td><td align="center">3 (2.95)</td><td align="center">0 (0.02)</td><td align="center">0.88</td><td align="center">1.1</td><td align="center">0.021<sup>5</sup></td></tr><tr><td></td><td align="center">(NA)<sup>6</sup></td><td></td><td align="center">Controls (73)</td><td align="center">0.014</td><td align="center">71 (71.01)</td><td align="center">2 (1.97)</td><td align="center">0 (0.01)</td><td align="center">0.91</td><td align="center">(0.2&#x02013;7.0)</td><td></td></tr><tr><td colspan="11"><hr></hr></td></tr><tr><td align="center">13</td><td align="center">c.703-18G/A</td><td align="center">Intron 6</td><td align="center">Cases (97)</td><td align="center">0.026</td><td align="center">92 (92.06)</td><td align="center">5 (4.87)</td><td align="center">0 (0.06)</td><td align="center">0.79</td><td align="center">3.9</td><td></td></tr><tr><td></td><td align="center">(rs769418)</td><td></td><td align="center">Controls (73)</td><td align="center">0.007</td><td align="center">72 (72.00)</td><td align="center">1 (0.99)</td><td align="center">0 (0)</td><td align="center">0.95</td><td align="center">(0.4&#x02013;34.2)</td><td></td></tr><tr><td colspan="11"><hr></hr></td></tr><tr><td align="center">14</td><td align="center">c.896+36G/A</td><td align="center">Intron 7</td><td align="center">Cases (97)</td><td align="center">0.026</td><td align="center">92 (92.06)</td><td align="center">5 (4.87)</td><td align="center">0 (0.06)</td><td align="center">0.79</td><td align="center">3.9</td><td align="center">0.021&#x02013;0.05<sup>5</sup></td></tr><tr><td></td><td align="center">(rs1805826)</td><td></td><td align="center">Controls (73)</td><td align="center">0.007</td><td align="center">72 (72.00)</td><td align="center">1 (0.99)</td><td align="center">0 (0)</td><td align="center">0.95</td><td align="center">(0.4&#x02013;34.2)</td><td></td></tr><tr><td colspan="11"><hr></hr></td></tr><tr><td align="center">15</td><td align="center">c.897-42G/C</td><td align="center">Intron 7</td><td align="center">Cases (97)</td><td align="center">0.015</td><td align="center">94 (94.02)</td><td align="center">3 (2.95)</td><td align="center">0 (0.02)</td><td align="center">0.76</td><td align="center">0.4</td><td></td></tr><tr><td></td><td align="center">(NA)<sup>6</sup></td><td></td><td align="center">Controls (73)</td><td align="center">0.034</td><td align="center">68 (68.09)</td><td align="center">5 (4.83)</td><td align="center">0 (0.09)</td><td align="center">0.76</td><td align="center">(0.1&#x02013;1.9)</td><td></td></tr><tr><td colspan="11"><hr></hr></td></tr><tr><td align="center">16</td><td align="center">c.994+233G/A</td><td align="center">Intron 8</td><td align="center">Cases (97)</td><td align="center">0.294</td><td align="center">50 (48.37)</td><td align="center">37 (40.25)</td><td align="center">10 (8.37)</td><td align="center">0.43</td><td align="center">0.7</td><td align="center">0.28<sup>5</sup></td></tr><tr><td></td><td align="center">(rs6990969)</td><td></td><td align="center">Controls (74)</td><td align="center">0.311</td><td align="center">34 (35.15)</td><td align="center">34 (31.70)</td><td align="center">6 (7.15)</td><td align="center">0.53</td><td align="center">(0.4&#x02013;1.4)</td><td></td></tr><tr><td colspan="11"><hr></hr></td></tr><tr><td align="center">17</td><td align="center">c.1124+18C/T</td><td align="center">Intron 9</td><td align="center">Cases (97)</td><td align="center">0.278</td><td align="center">52 (50.52)</td><td align="center">36 (38.97)</td><td align="center">9 (7.52)</td><td align="center">0.45</td><td align="center">0.7</td><td align="center">0.09&#x02013;0.306<sup>5</sup></td></tr><tr><td></td><td align="center">(rs2234744)</td><td></td><td align="center">Controls (74)</td><td align="center">0.304</td><td align="center">35 (35.84)</td><td align="center">33 (31.32)</td><td align="center">6 (6.84)</td><td align="center">0.64</td><td align="center">(0.4&#x02013;1.4)</td><td></td></tr><tr><td colspan="11"><hr></hr></td></tr><tr><td align="center">18</td><td align="center">c.1124+91C/A</td><td align="center">Intron 9</td><td align="center">Cases (97)</td><td align="center">0.273</td><td align="center">53 (51.24)</td><td align="center">35 (38.52)</td><td align="center">9 (7.24)</td><td align="center">0.37</td><td align="center">0.7</td><td align="center">0.283&#x02013;0.306<sup>5</sup></td></tr><tr><td></td><td align="center">(rs1805818)</td><td></td><td align="center">Controls (74)</td><td align="center">0.304</td><td align="center">35 (35.84)</td><td align="center">33 (31.32)</td><td align="center">6 (6.84)</td><td align="center">0.64</td><td align="center">(0.4&#x02013;1.3)</td><td></td></tr><tr><td colspan="11"><hr></hr></td></tr><tr><td align="center">19</td><td align="center">c.1125-79C/A</td><td align="center">Intron 9</td><td align="center">Cases (97)</td><td align="center">0.284</td><td align="center">52 (49.80)</td><td align="center">35 (39.41)</td><td align="center">10 (7.80)</td><td align="center">0.27</td><td align="center">0.8</td><td align="center">0.323<sup>5</sup></td></tr><tr><td></td><td align="center">(rs1805786)</td><td></td><td align="center">Controls (72)</td><td align="center">0.292</td><td align="center">36 (36.13)</td><td align="center">30 (29.75)</td><td align="center">6 (6.13)</td><td align="center">0.94</td><td align="center">(0.4&#x02013;1.5)</td><td></td></tr><tr><td colspan="11"><hr></hr></td></tr><tr><td align="center">20</td><td align="center">c.1915-7A/G</td><td align="center">Intron 12</td><td align="center">Cases (97)</td><td align="center">0.284</td><td align="center">52 (49.80)</td><td align="center">35 (39.41)</td><td align="center">10 (7.80)</td><td align="center">0.27</td><td align="center">0.8</td><td align="center">0.20&#x02013;0.312<sup>5</sup></td></tr><tr><td></td><td align="center">(rs2308962)</td><td></td><td align="center">Controls (70)</td><td align="center">0.300</td><td align="center">34 (34.30)</td><td align="center">30 (29.40)</td><td align="center">6 (6.30)</td><td align="center">0.86</td><td align="center">(0.4&#x02013;1.5)</td><td></td></tr><tr><td colspan="11"><hr></hr></td></tr><tr><td align="center">21</td><td align="center">c.2071-30A/T</td><td align="center">Intron 13</td><td align="center">Cases (97)</td><td align="center">0.284</td><td align="center">52 (49.80)</td><td align="center">35 (39.41)</td><td align="center">10 (7.80)</td><td align="center">0.27</td><td align="center">0.7</td><td></td></tr><tr><td></td><td align="center">(rs3736639)</td><td></td><td align="center">Controls (71)</td><td align="center">0.310</td><td align="center">33 (33.82)</td><td align="center">32 (30.37)</td><td align="center">6 (6.82)</td><td align="center">0.65</td><td align="center">(0.4&#x02013;1.3)</td><td></td></tr><tr><td colspan="11"><hr></hr></td></tr><tr><td align="center">22</td><td align="center">c.2234+86T/G</td><td align="center">Intron 15</td><td align="center">Cases (97)</td><td align="center">0.010</td><td align="center">95 (95.01)</td><td align="center">2 (1.98)</td><td align="center">0 (0.01)</td><td align="center">0.92</td><td align="center">3.8</td><td></td></tr><tr><td></td><td align="center">(NA)</td><td></td><td align="center">Controls (72)</td><td align="center">0.000</td><td align="center">72 (72.00)</td><td align="center">0 (0)</td><td align="center">0 (0)</td><td align="center">1.00</td><td align="center">(0.2&#x02013;80.3)</td><td></td></tr><tr><td colspan="11"><hr></hr></td></tr><tr><td align="center">23</td><td align="center">c.2234+88C/G</td><td align="center">Intron 15</td><td align="center">Cases (97)</td><td align="center">0.015</td><td align="center">94 (94.02)</td><td align="center">3 (2.95)</td><td align="center">0 (0.02)</td><td align="center">0.88</td><td align="center">0.4</td><td align="center">0.017&#x02013;0.042<sup>5</sup></td></tr><tr><td></td><td align="center">(rs13312970)</td><td></td><td align="center">Controls (71)</td><td align="center">0.035</td><td align="center">66 (66.09)</td><td align="center">5 (4.82)</td><td align="center">0 (0.09)</td><td align="center">0.76</td><td align="center">(0.1&#x02013;1.8)</td><td></td></tr><tr><td colspan="11"><hr></hr></td></tr><tr><td align="center">24</td><td align="center">c.2234+157A/G</td><td align="center">Intron 15</td><td align="center">Cases (97)</td><td align="center">0.046</td><td align="center">88 (88.21)</td><td align="center">9 (8.58)</td><td align="center">0 (0.21)</td><td align="center">0.63</td><td align="center">2.3</td><td align="center">0.000&#x02013;0.025<sup>5</sup></td></tr><tr><td></td><td align="center">(rs13312971)</td><td></td><td align="center">Controls (71)</td><td align="center">0.021</td><td align="center">68 (68.03)</td><td align="center">3 (2.94)</td><td align="center">0 (0.03)</td><td align="center">0.86</td><td align="center">(0.6&#x02013;8.9)</td><td></td></tr></tbody></table><table-wrap-foot><p><sup>1 </sup>According to the nomenclature guidelines of the Human Genome Variation Society (reference sequence NM_002485.4), nucleotide number one being the A from the ATG codon. <sup>2 </sup>Minor allele frequency <sup>3 </sup>As expected under Hardy-Weinberg equilibrium <sup>4 </sup>Odds ratios for comparison of heterozygotes versus common homozygotes <sup>5 </sup>From NCBI dbSNP data. <sup>6 </sup>No entry in NCBI dbSNP database, although reported in the literature.</p></table-wrap-foot></table-wrap><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Schematic representation of the <italic>NBN </italic>gene on chromosome 8q21</bold>. The upper part shows variants identified in the <italic>NBN </italic>gene. Light green boxes refer to SNPs with MAF &#x02265; 5% in the cases set, and variants name are indicated according to the reference sequence NM_002485.4. Corresponding coding variations are indicated relative to the protein structure in the bottom part of the figure. Light blue boxes refer to synonymous variations. FHA: Forkhead-associated domain. BRCT: BRCA1 C-terminal domain. MIR: MRE11 interacting region. AIR: ATM interacting region. Yellow dots: acetylated lysine residues (K208, K233, K334, K441, K504, K544, K665, K690, K698 and K715). Red dots: phosphorylated serine residues (S278 and S343).</p></caption><graphic xlink:href="1471-2407-9-181-1"/></fig></sec><sec><title>Identification of NBN alternative splice forms</title><p>Analysis of <italic>NBN </italic>cDNA was also performed on a subset of these breast cancer cases and highlighted the presence of two distinct alternative splice events. The first splice variant involved the insertion of 50 bp of the intron between exons 2 and 3 and is expected to result in a premature stop codon [<xref ref-type="bibr" rid="B29">29</xref>]. The other alternative splice form identified involves the skipping of exons 12 to 14 which is expected to produce an in-frame deletion of 113 amino acids in the region of the NBN protein involved in the interaction with its partner MRE11A (Figure <xref ref-type="fig" rid="F1">1</xref>). However, QRT-PCR of this specific form was performed on cDNA samples from a subset of 10 breast cancer cases from our cohort and showed a very low expression relative to the main isoform (data not shown), which is consistent with previous work [<xref ref-type="bibr" rid="B30">30</xref>].</p><p><italic>In silico </italic>analysis of the putative impact of NBN exonic and intronic sequence variants on these splice events was also performed. Analysis of the nine exonic sequence variants using ESEfinder indicated that, while five variants (c.283G/A, c.553G/C, c.643C/T, c.797C/T, and c.1197T&#x0003e;C) might have an impact on putative score motifs of four SR proteins, a closer examination of these results shows that these scores, while below the program thresholds, remain relatively high and thus are unlikely to affect <italic>NBN </italic>constitutive splicing (Figure <xref ref-type="fig" rid="F2">2</xref>). According to the Splice Site prediction program, the intronic variant c.896+36G/A might slightly increase a putative acceptor site (score from 0.66 to 0.75). However, this was not confirmed by the Splice Site Finder program, which predicted the abolition of a putative donor site with a score of 71.2. As for the c.1124+91C/A intronic variant, only the Splice Site Prediction program predicted the abolition of a weak acceptor site (score of 0.45) while for the c.2234+157A/G intronic variant, the Splice Site Finder program estimated the creation of a putative acceptor site with a score of 77.2. Hence, none of the variants identified are expected to be responsible for the alternative splice events observed.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold><italic>In silico </italic>analysis of the effect of coding variants on putative exonic splicing enhancer (ESE) motifs by the ESEfinder program</bold>. Only scores for predicted motifs potentially abolished by exonic variants are shown. Light gray: motif matrix scores for consensus sequences. Dark gray: motif matrix scores for variant sequences. The name of the SR protein potentially involved is indicated for each score pair. Doted line indicates the default threshold used by ESEfinder for the corresponding motif.</p></caption><graphic xlink:href="1471-2407-9-181-2"/></fig></sec><sec><title>Effect of the c.-242-110delAGTA variant on luciferase reporter gene expression</title><p>The putative effect of the c.-242-110delAGTA variant located in the promoter region was also assessed by the MatInspector program, which predicts that this variant may abolish recognition motifs for the ZFHX3/ATBF1 (Zinc finger homeobox 3, or AT motif-binding factor 1), NKX3-1 (NK3 homeobox 1) and CDX2 (Caudal-type homeobox 2) transcription factors, and create a potential binding site for the MTBF (Muscle-specific MT binding factor) transcription factor (Figure <xref ref-type="fig" rid="F3">3A</xref>). The effect of the c.-242-110delAGTA variant on <italic>NBN </italic>expression was therefore further assessed using a dual reporter gene system. MCF-7, LNCaP, HeLa and HEK293 cells were then transiently transfected with a construct containing the consensus <italic>NBN </italic>sequence or with the variant sequence, together with the <italic>Renilla </italic>reporter plasmid as an internal transfection control (Figure <xref ref-type="fig" rid="F3">3B</xref>). While no significant difference in expression was observed between both constructs in MCF-7 and HeLa cells, a slight diminution of luciferase expression was observed for the variant construct relative to the reference sequence construct in both the HEK293 and LNCaP cell lines (Figure <xref ref-type="fig" rid="F3">3C</xref>). Interestingly, QRT-PCR measures indicated that ATBF1 mRNA is 2.4 times more expressed in HeLa cells, and more than 4.3 times more expressed in LNCaP cells, than in MCF-7 cells (data not shown).</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Effect of the c.-242-110delAGTA deletion on <italic>NBN</italic>promoter activity</bold>. Panel A shows the results of the <italic>in silico </italic>predictions of transcription factors binding sites affected by the c.-242-110delAGTA variant obtained from the MatInspector program. Panel B shows the schematic representation of the two reporter gene constructs containing the <italic>NBN </italic>promoter used in this study. The positions relative to the nucleotide A of the <italic>NBN </italic>reference sequence ATG codon are indicated. Panel C shows the results of the luciferase reporter assay. MCF-7, LNCaP, HeLa and HEK293 cells were transiently co-transfected with the <italic>Renilla </italic>reporter plasmid (pRL) as a transfection control. Each data represents mean &#x000b1; standard deviation of triplicates. Data are shown as fold of induction compared to the activity of cells transfected with the empty pGL3-basic luciferase reporter vector. *p = 0.0245 **p = 0.0181</p></caption><graphic xlink:href="1471-2407-9-181-3"/></fig></sec><sec><title>LD analysis across NBN genomic sequence and haplotypes determination</title><p>Pairwise LD measures of all variants using the control dataset are presented in Figure <xref ref-type="fig" rid="F4">4</xref>. |D'| values show a high degree of LD for all SNP pairs while the more stringent r<sup>2 </sup>measure, dependent upon allele frequency, shows a limited block of LD involving mainly SNPs located in the second half of the <italic>NBN </italic>gene. The bottom part of Figure <xref ref-type="fig" rid="F4">4</xref> shows the r<sup>2 </sup>HapMap CEU data in the vicinity of <italic>NBN </italic>on chromosome 8, and suggests that <italic>NBN </italic>may overlap two blocks of LD. The major part of <italic>NBN </italic>seems to be in a strong block of LD extending 5' of the gene, while its 3' extremity spans over another smaller block.</p><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Linkage disequilibrium across the <italic>NBN </italic>gene and neighbouring chromosomal region</bold>. Upper part shows linkage disequilibrium (LD) results (r<sup>2 </sup>and |D'|) obtained from the control genotypes data used in our study and their relative position along <italic>NBN </italic>sequence. In the bottom part of the figure are indicated r<sup>2 </sup>data from the International HapMap project (release 21a) for the genomic region encompassing <italic>NBN</italic>. The intensity of the box color is proportional to the strength of LD. r<sup>2 </sup>= 0 in white; 0 &#x0003c; r<sup>2 </sup>&#x0003c; 1 in shades of pink/red; r<sup>2 </sup>= 1 in bright red.</p></caption><graphic xlink:href="1471-2407-9-181-4"/></fig><p>Haplotype phasing of <italic>NBN </italic>using the WHAP program with all 24 variants identified in our datasets indicated that 14 haplotypes are present with an estimated frequency greater than 0.5%. Although WHAP did not estimate a significant difference between both groups, the p-value observed was borderline significant (p = 0.0588). The majority of these estimated haplotypes (84.5%) have a frequency greater than 2%. Two haplotypes (#4 and #7 in Table <xref ref-type="table" rid="T4">4</xref>) showed a weak significant association with breast cancer, being more frequent among cases (p = 0.0205 and p = 0.0403, respectively). The same analysis, using only common variations (MAF &#x0003e;5%), suggested that one haplotype is more frequent among cases than controls (WH4, p = 0.0227), with another haplotype showing a non-significant trend of over-representation in cases (WH5, p = 0.0883) (Table <xref ref-type="table" rid="T5">5</xref>). Global estimation of haplotypes was further confirmed using the PHASE 2.1.1 program, with concordant results (data not shown).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Estimated haplotypes using the WHAP program and all variants identified, for cases and controls combined.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td></td><td align="center" colspan="3">Estimated Haplotype Frequencies</td><td></td></tr><tr><td></td><td></td><td colspan="3"><hr></hr></td><td></td></tr><tr><td align="center">Haplotype</td><td align="center">SNPs<sup>1</sup><break/>10-1-2-3-4-5-6-11-12-13-7-14-15-16-17-18-19-8-20-9-21-22-23-24</td><td align="center">Cases</td><td align="center">Controls</td><td align="center">Combined</td><td align="center">p-value<sup>2</sup></td></tr></thead><tbody><tr><td align="center">1</td><td align="center">TGGTAGCTCGCGGGCCCTAAATCA</td><td align="center">0.481</td><td align="center">0.486</td><td align="center">0.483</td><td align="center">0.92</td></tr><tr><td align="center">2</td><td align="center">TAGTACCTCGCGGATAACGGTTCA</td><td align="center">0.232</td><td align="center">0.255</td><td align="center">0.244</td><td align="center">0.636</td></tr><tr><td align="center">3</td><td align="center">TGGTAGCCCGCGGGCCCTAAATCA</td><td align="center">0.065</td><td align="center">0.097</td><td align="center">0.078</td><td align="center">0.29</td></tr><tr><td align="center">4</td><td align="center">AGGTAGCTCGCGGGCCCTAAATCA</td><td align="center">0.089</td><td align="center">0.030</td><td align="center">0.052</td><td align="center">0.0205</td></tr><tr><td align="center">5</td><td align="center">TAGTAGCTCGCGGATAACGGTTCA</td><td align="center">0.036</td><td align="center">0.007</td><td align="center">0.022</td><td align="center">0.147</td></tr><tr><td align="center">6</td><td align="center">TGGTAGCTCGCGCGCCCTAAATCA</td><td align="center">0.012</td><td align="center">0.036</td><td align="center">0.021</td><td align="center">0.146</td></tr><tr><td align="center">7</td><td align="center">TAGTACCTCGCGGATAACGGTTGA</td><td align="center">0.006</td><td align="center">0.037</td><td align="center">0.019</td><td align="center">0.0403</td></tr><tr><td align="center">8</td><td align="center">TGGTAGCTCGCGGGCCCTAAATCG</td><td align="center">0.019</td><td align="center">0.022</td><td align="center">0.015</td><td align="center">0.846</td></tr><tr><td align="center">9</td><td align="center">TGGTAGCTCACAGGCCCCAAATCA</td><td align="center">0.013</td><td align="center">0.000</td><td align="center">0.011</td><td align="center">0.11</td></tr><tr><td align="center">10</td><td align="center">TGGTACCTCGCGGGCCCTAAATCA</td><td align="center">0.012</td><td align="center">0.008</td><td align="center">0.010</td><td align="center">0.749</td></tr><tr><td align="center">11</td><td align="center">TGGTAGCTTGCGGGCCCTAAATCA</td><td align="center">0.006</td><td align="center">0.014</td><td align="center">0.008</td><td align="center">0.47</td></tr><tr><td align="center">12</td><td align="center">TGGTAGCTCGCGGACCCTAAATCA</td><td align="center">0.006</td><td align="center">0.007</td><td align="center">0.006</td><td align="center">0.897</td></tr><tr><td align="center">13</td><td align="center">TGGTAGCTTGCGGGCCCTAAATCG</td><td align="center">0.011</td><td align="center">0.000</td><td align="center">0.006</td><td align="center">0.126</td></tr><tr><td align="center">14</td><td align="center">TGGTAGCTCACAGGCCCCAAATCG</td><td align="center">0.011</td><td align="center">0.008</td><td align="center">0.006</td><td align="center">0.128</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>SNPs identification as in Table 2 and 3. <sup>2 </sup>p-value for haplotype-specific test, each haplotype versus all other haplotypes.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Estimated haplotypes using the WHAP program and SNPs with a frequency greater than 5% for cases and controls combined.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td></td><td align="center" colspan="3">Estimated Haplotype Frequencies</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="3"><hr></hr></td><td></td><td></td></tr><tr><td align="center">Haplotype</td><td align="center">SNPs<sup>1</sup><break/>10-1-5-11-16-17-18-19-8-20-9-21</td><td align="center">Cases</td><td align="center">Controls</td><td align="center">Combined</td><td align="center">p-value<sup>2</sup></td><td align="center">OR (95%CI)</td></tr></thead><tbody><tr><td align="center">WH1</td><td align="center">TGGTGCCCTAAA</td><td align="center">0.511</td><td align="center">0.558</td><td align="center">0.538</td><td align="center">0.361</td><td align="center">REF</td></tr><tr><td align="center">WH2</td><td align="center">TACTATAACGGT</td><td align="center">0.250</td><td align="center">0.293</td><td align="center">0.264</td><td align="center">0.399</td><td align="center">0.9 (0.6&#x02013;1.6)</td></tr><tr><td align="center">WH3</td><td align="center">TGGCGCCCTAAA</td><td align="center">0.065</td><td align="center">0.096</td><td align="center">0.080</td><td align="center">0.277</td><td align="center">0.7 (0.3&#x02013;1.7)</td></tr><tr><td align="center">WH4</td><td align="center">AGGTGCCCTAAA</td><td align="center">0.087</td><td align="center">0.030</td><td align="center">0.059</td><td align="center">0.0227</td><td align="center">3.2 (1.1&#x02013;9.2)</td></tr><tr><td align="center">WH5</td><td align="center">TGGTGCCCCAAA</td><td align="center">0.038</td><td align="center">0.008</td><td align="center">0.027</td><td align="center">0.0883</td><td align="center">5.1 (0.9&#x02013;30.1)</td></tr><tr><td align="center">WH6</td><td align="center">TAGTATAACGGT</td><td align="center">0.033</td><td align="center">0.007</td><td align="center">0.021</td><td align="center">0.176</td><td align="center">7.8 (0.8&#x02013;30.5)</td></tr><tr><td align="center">WH7</td><td align="center">TGCTGCCCTAAA</td><td align="center">0.017</td><td align="center">0.008</td><td align="center">0.011</td><td align="center">0.542</td><td align="center">2.4 (0.3&#x02013;16.1)</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>SNPs identification as in Table 2 and 3.<sup>2</sup>p-value for haplotype-specific test, each haplotype versus all other haplotypes.</p></table-wrap-foot></table-wrap><p>A closer examination of these two haplotypes (WH4 and WH5) showed that the only variation present on WH4 is the c.-242-110delAGTA variant, which on its own shows a significant difference in frequency between both groups. Thus, this variant is likely to be responsible of the association observed as any further breakdown of this haplotype using a sliding window analysis shows that all combinations involving this variant display a significant association (data not shown). As for the WH5 haplotype carrying the c.1197T/C variant in exon 10, it does not show any significant difference in frequency between the both groups and, despite its strong linkage disequilibrium with the adjacent variants, it shows only a tendency towards significativity when present in combination with the major alleles at all other positions (Table <xref ref-type="table" rid="T5">5</xref>).</p></sec></sec><sec><title>Discussion</title><p>Although the relevance of mutations in several DNA repair genes (<italic>BRCA1, BRCA2, TP53, PTEN, PALB2, BRIP1</italic>) in breast cancer susceptibility have been well established, the association of variants in other genes, potentially accounting for the remaining familial clustering, is not well defined. For example, heterozygous carriers of deleterious mutations in the <italic>NBN </italic>gene, in particular the Slavic founder mutation 657del5, has been associated with a 2- to 3-fold increased risk of cancer [<xref ref-type="bibr" rid="B6">6</xref>]. However the impact of other <italic>NBN </italic>variants on cancer risk is unclear. Nonetheless, studies have demonstrated an increased spontaneous chromosomal instability in cells from heterozygous carriers of <italic>NBN </italic>mutations [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. In addition, the presence of a specific pattern of gene expression involving pathways of DNA repair and damage bypass, mitotic checkpoint and apoptosis was demonstrated, suggesting that cells from these carriers may display a much less efficient DNA repair system [<xref ref-type="bibr" rid="B31">31</xref>]. In this regard, a recent study by Someya et al. [<xref ref-type="bibr" rid="B32">32</xref>] showed a correlation between persistent radiation-induced NBN foci and both chromosomal instability and sporadic breast cancer risk. To address the possible implication of <italic>NBN </italic>sequence variants on breast cancer risk, we took advantage of our resource of high-risk breast cancer families drawn from the French Canadian population. In order to increase the statistical power of our investigation, one affected individual from each family was selected for analysis [<xref ref-type="bibr" rid="B33">33</xref>], each thoroughly screened for <italic>BRCA1 </italic>and <italic>BRCA2 </italic>mutations or large genomic rearrangements in these genes [<xref ref-type="bibr" rid="B21">21</xref>].</p><p>The majority of the coding variants identified in our cohort of breast cancer cases are situated in the forkhead-associated (FHA) domain and the two BRCT domains, and these domains have been demonstrated to be essential to NBN binding to the histone &#x003b3;-H2AX [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>]. One of the rare variants identified in this study, p.Ile171Val, was first described in acute lymphoblastic leukemia (ALL) patients [<xref ref-type="bibr" rid="B36">36</xref>]. This variant has been previously reported to be over-represented in some cancer cohorts [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B38">38</xref>], and has also been previously described at the homozygous state in a Japanese NBS patient affected with aplastic anemia and genomic instability [<xref ref-type="bibr" rid="B39">39</xref>]. Interestingly, analysis of the patient's and her father's lymphoblastoid cell lines demonstrated a higher frequency of spontaneous chromosomal aberrations compared with healthy controls (6- and 4-fold increase, respectively). These results suggest that the p.Ile171Val variation may be deleterious, also supported by the fact that this variant alters an amino acid which is conserved in species such as the chicken and the fruitfly [<xref ref-type="bibr" rid="B39">39</xref>]. However, the impact of the p.Ile171Val substitution remains to be clarified as a large study, including cases from Germany and the Republic of Belarus, did not find any association with breast cancer in those populations [<xref ref-type="bibr" rid="B40">40</xref>].</p><p>Another rare variant, p.Arg215Trp, has been considered pathogenic in previous studies based on its highly conserved position and the change introduced. Moreover, this variant has been identified in monozygotic twins compound heterozygotes for 657del5/p.Arg215Trp and affected with a severe form of NBS [<xref ref-type="bibr" rid="B41">41</xref>]. Nibrin<sup>Trp215 </sup>appears to affect the correct nibrin function, and cells carrying this variant shows delayed DNA DSB rejoining [<xref ref-type="bibr" rid="B41">41</xref>]. Modelisation of the tandem BRCT domains suggests that the Arg215 residue is required for correct orientation of the BRCT domains and recognition of &#x003b3;-H2AX [<xref ref-type="bibr" rid="B34">34</xref>]. In their experiment, nibrin<sup>Trp215 </sup>seems to partially interfere with nibrin<sup>Arg215 </sup>activity and may act in a co-dominant fashion. It is also interesting to note that although this variant is relatively frequent in several studies, to our knowledge no NBS cases homozygous for this variant have been reported.</p><p>Of the other rare variants present in our cohort of breast cancer cases, the p.Pro266Leu variant was observed in one breast cancer case, and the p.Asp95Asn variant was found in one breast cancer case and one control. Although these variants involve conserved residues, their putative effect on protein function remains unclear. In a previous study on non-Hodgkin lymphoma, both variants were detected only in healthy controls [<xref ref-type="bibr" rid="B42">42</xref>]. Regarding the p.Asp95Asn variant first identified in an ALL patient [<xref ref-type="bibr" rid="B36">36</xref>], no association was found in a study of larynx cancer [<xref ref-type="bibr" rid="B38">38</xref>] or ALL [<xref ref-type="bibr" rid="B37">37</xref>]. This variant was found in one out of 613 and 121 unselected and familial prostate cancer cases, respectively, but not in controls [<xref ref-type="bibr" rid="B43">43</xref>]. However, p.Asp95Asn is not predicted to be highly damaging as its expression in NBS cells seems to have a similar activity to the wild type protein [<xref ref-type="bibr" rid="B42">42</xref>]. The only other non-synonymous change identified in our cohort is the p.Glu185Gln common variant (MAF &#x0003e;25%), which has been genotyped in several association studies. Although the majority of the studies analyzing this variant found no association with cancer [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B38">38</xref>,<xref ref-type="bibr" rid="B42">42</xref>-<xref ref-type="bibr" rid="B44">44</xref>], some studies reported an association with breast cancer [<xref ref-type="bibr" rid="B8">8</xref>], basal cell carcinoma in men [<xref ref-type="bibr" rid="B45">45</xref>] and a recent meta-analysis of this variant in bladder cancer revealed a significant association after controlling for potential bias [<xref ref-type="bibr" rid="B46">46</xref>]. In addition, Musak et al. [<xref ref-type="bibr" rid="B47">47</xref>] reported that this variant may modulate the frequency of chromatid-type aberrations among tire plant workers. However, our data do not allow us to confirm any positive association.</p><p>Among the non-coding variants, a possible association of the c.-242-110delAGTA variant with an increased risk of breast cancer could be observed (OR 3.4 95% CI: 1.1&#x02013;10.5). This association was further confirmed by the estimation of the haplotype diversity in our dataset, which highlighted the presence of the haplotype bearing the c.-242-110delAGTA variant at a higher frequency among the breast cancer case subset. <italic>In silico </italic>prediction of putative transcription factor binding sites indicated that of the four transcription factor binding sites potentially affected by the deletion, some are predicted to involve proteins not expressed in the breast. MTBF acts in the muscle regulation of the myostatin gene [<xref ref-type="bibr" rid="B48">48</xref>], while CDX2 is mainly expressed in the gut although its ectopic expression was also reported in cases of non-gastrointestinal carcinomas [<xref ref-type="bibr" rid="B49">49</xref>]. As for the transcription factor NKX3-1, it is mainly expressed in the prostate although it is also found at low levels in the mammary gland and breast tumors, and has been suggested to act as a haplo-insufficient tumor suppressor in prostate cancer [<xref ref-type="bibr" rid="B50">50</xref>]. The fourth transcription factor potentially affected is ATBF1 (also known as ZFHX3). ATBF1 was shown to suppress the expression of the alpha-fetoprotein [<xref ref-type="bibr" rid="B51">51</xref>] and the MYB oncogene [<xref ref-type="bibr" rid="B52">52</xref>]. ATBF1 also cooperates with p53 to activate the <italic>CDKN1A </italic>promoter and trigger cell cycle arrest [<xref ref-type="bibr" rid="B53">53</xref>]. ATBF1 is expressed in the mammary gland and breast tumors (NCBI's UNIGENE data), and the expression of ATBF1 mRNA was correlated with a better prognosis in 153 patients with invasive carcinomas of the breast [<xref ref-type="bibr" rid="B54">54</xref>]. This might suggest that deregulation of genes controlled through ATBF1 could have an important impact on breast cancer formation and progression.</p><p>Luciferase reporter gene assay using the promoter sequence proximal to the ATG codon indicated a similar level of expression of the c.-242-110delAGTA variant allele as compared to the reference sequence construct in the breast cancer cell line MCF-7 and in HeLa cells. However, a slight decrease in luciferase expression was observed in both HEK293 and LNCaP cells, which might indicate that this variant could have an impact on <italic>NBN </italic>expression in a cell type manner. The analysis of <italic>ATBF1 </italic>gene expression indicated that this transcription factor is weakly expressed, in particular in the MCF-7 cells. This is comparable to a recent study performed on a panel of 32 breast cancer cell lines, which indicated that in 75% of these cell lines, <italic>ATBF1 </italic>is expressed at 50% or less relative to the normal breast [<xref ref-type="bibr" rid="B55">55</xref>]. This could in turn explain the lack of effect observed for the luciferase assay in the MCF-7 cell line. On the other hand, one could hypothesize that <italic>NBN </italic>(or transcription factors affecting its expression) may be regulated following irradiation or other genotoxic stress. Additional research will however be needed to address this possibility, as well as binding experiments to confirm ATFB1 binding to this region of the promoter. However, it is also important to keep in mind that the promoter sequence cloned here, although supporting <italic>NBN </italic>expression, is unlikely to constitute the entire <italic>NBN </italic>promoter. It is indeed plausible that transcription factors acting on the proximal sequence might be influenced by other transcription factors acting further upstream. As such, despite the lack of variation in expression induction found in MCF-7 by luciferase assay, it is possible that the c.-242-110delAGTA variant could be in LD with another functional variant located elsewhere in the promoter, as a high degree of LD is present across the whole <italic>NBN </italic>gene. Unfortunately, the promoter variant could not be associated by LD with another variant in the coding region of the gene, which would have allowed to directly measure <italic>NBN </italic>allelic expression.</p></sec><sec><title>Conclusion</title><p>Our analysis suggests that the variant c.-242-110delAGTA identified in our cohort of breast cancer individuals and located in the promoter region of the <italic>NBN </italic>gene may be associated with an increased risk of breast cancer. However, the functional analysis by luciferase promoter assay does not support a causative effect of this variant in the breast cancer cell line MCF-7, although a reduction of luciferase expression driven by the <italic>NBN </italic>promoter can be observed in two other cell lines tested. As the <italic>NBN </italic>genomic region displays a high degree of LD, we cannot rule out the effect of other variants located upstream of the region analyzed here. Alternatively, the effect of this variant may be dependent upon induction by a genotoxic stress such as irradiation. Although NBS is a rare syndrome, carriers of deleterious alterations in this gene are more common and may display subtle manifestations in cellular pathways predisposing <italic>NBN</italic>-mutated carriers to malignancy. Further analyses will therefore be needed to ascertain the impact of rare variants and promoter variants of <italic>NBN </italic>on breast cancer susceptibility in other populations.</p></sec><sec><title>Abbreviations</title><p>AIR: ATM interacting region; ALL: Acute lymphoblastic leukemia; ATBF1: AT motif-binding factor 1; BRCT: BRCA1 C-terminal; CDX2: Caudal-type homeobox 2; CI: Confidence interval; DSB: Double strand breaks; ESE: Exonic splicing enhancer; FHA: Forkhead-associated; HWE: Hardy-Weinberg equilibrium; LD: Linkage disequilibrium; MAF: Minor allele frequency; MIR: MRE11A interacting region; MTBF1: Muscle-specific MT binding factor; NBS: Nijmegen breakage syndrome; NKX3-1: NK3 homeobox 1; OR: Odds ratio; QRT-PCR: Quantitative real-time PCR; ZFHX3: Zinc finger homeobox 3.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>SD participated in the molecular analysis study, performed the reporter gene assays experiments and bioinformatics analyses, and drafted the manuscript. CJB participated in the molecular analysis study. YL provided technical assistance and helped draft the manuscript. GO performed DNA and RNA extractions, cell maintenance and participated in the luciferase assays experiments. FD conceived the study, its design and coordination, and authored the final version of the manuscript. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/9/181/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>The authors would like to thank all individuals and families who participated in this study. We thank C. Brousseau, Dr. S. D&#x000e9;los, M.-A. Lajoie, P. L&#x000e9;ger, J. Rh&#x000e9;aume, C. Samson, M. Tranchant, Dr. M. Dumont, G. Leblanc, H. Malouin, N. Bolduc, A. MacMillan and T. Babineau of the Cancer Genomics Laboratory for genetic counselling, sample management and mutation screening. We also thank F. Gu&#x000e9;nard for advices regarding luciferase assays, M. Ouellet and A.-M. Bureau-Blouin for skillful technical help and Dr. D. Labuda and C. Moreau at the Centre de Canc&#x000e9;rologie Charles Bruneau of Ste-Justine Hospital for help with control DNA samples.</p><p>Other members of INHERIT BRCAs involved in this study are as follow: Paul Bessette: Service de gyn&#x000e9;cologie, Centre Hospitalier Universitaire de Sherbrooke, Fleurimont, QC, Canada; Jocelyne Chiquette: Clinique des maladies du sein Desch&#x000ea;nes-Fabia, H&#x000f4;pital du Saint-Sacrement, Qu&#x000e9;bec, QC, Canada; Rachel Laframboise: Service de m&#x000e9;decine g&#x000e9;n&#x000e9;tique, CHUQ, Pavillon CHUL, Qu&#x000e9;bec, QC, Canada; Jean L&#x000e9;pine: Centre Hospitalier r&#x000e9;gional de Rimouski, Rimouski, QC, Canada; Bernard Lesp&#x000e9;rance, Roxane Pichette: Service d'h&#x000e9;mato-oncologie, H&#x000f4;pital du Sacr&#x000e9;-C&#x00153;ur, Montr&#x000e9;al, QC, Canada; Marie Plante: Service de gyn&#x000e9;cologie, CHUQ, L'H&#x000f4;tel-Dieu de Qu&#x000e9;bec, Qu&#x000e9;bec, Canada; Jacques Simard: Director and instigator of the integrated research program INHERIT BRCAs, and chairholder of the Canada Research Chair in Oncogenetics. Cancer Genomics Laboratory, Oncology and Molecular Endocrinology Research Centre, Centre Hospitalier Universitaire de Qu&#x000e9;bec and Laval University, Qu&#x000e9;bec, Canada.</p><p>This work was supported by the Canadian Institutes of Health Research (CIHR) and Institute of Cancer and Institute of Gender and Health for the INHERIT BRCAs research program, the Fond de la Recherche en Sant&#x000e9; du Qu&#x000e9;bec (FRSQ)/R&#x000e9;seau de M&#x000e9;decine G&#x000e9;n&#x000e9;tique Appliqu&#x000e9;e (RMGA), the Canadian Breast Cancer Research Alliance (CBCRA) and the CURE Foundation. S.D. holds studentships from Fondation Ren&#x000e9; Bussi&#x000e8;res and Fondation Desjardins, C.J.B. holds a Frederick Banting and Charles Best Canada Graduate Scholarships &#x02013; Master's Award studentship from CIHR, and F.D. is a recipient of a chercheur-boursier from the Fonds de la Recherche en Sant&#x000e9; du Qu&#x000e9;bec (FRSQ) and Research Career Award in the Health Sciences from CIHR/R&#x00026;D Health Research Foundation.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Rahman</surname><given-names>N</given-names></name></person-group><article-title>The emerging landscape of breast cancer susceptibility</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">18163131</pub-id><pub-id pub-id-type="doi">10.1038/ng.2007.53</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>RS</given-names></name><name><surname>Williams</surname><given-names>JS</given-names></name><name><surname>Tainer</surname><given-names>JA</given-names></name></person-group><article-title>Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template</article-title><source>Biochem Cell Biol</source><year>2007</year><volume>85</volume><fpage>509</fpage><lpage>520</lpage><pub-id pub-id-type="pmid">17713585</pub-id><pub-id pub-id-type="doi">10.1139/O07-069</pub-id></citation></ref><ref id="B3"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Durocher</surname><given-names>F</given-names></name><name><surname>Gu&#x000e9;nard</surname><given-names>F</given-names></name><name><surname>Desjardins</surname><given-names>S</given-names></name><name><surname>Ouellette</surname><given-names>G</given-names></name><name><surname>Labrie</surname><given-names>Y</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Sinnett D</surname></name></person-group><article-title>Inherited susceptibility to breast cancer: accomplishments and challenges</article-title><source>Molecular genetics of cancer</source><year>2005</year><publisher-name>Kerala: Research Signpost</publisher-name><fpage>9</fpage><lpage>93</lpage></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seemanova</surname><given-names>E</given-names></name></person-group><article-title>An increased risk for malignant neoplasms in heterozygotes for a syndrome of microcephaly, normal intelligence, growth retardation, remarkable facies, immunodeficiency and chromosomal instability</article-title><source>Mutat Res</source><year>1990</year><volume>238</volume><fpage>321</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">2342514</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Howlett</surname><given-names>NG</given-names></name><name><surname>Scuric</surname><given-names>Z</given-names></name><name><surname>D'Andrea</surname><given-names>AD</given-names></name><name><surname>Schiestl</surname><given-names>RH</given-names></name></person-group><article-title>Impaired DNA double strand break repair in cells from Nijmegen breakage syndrome patients</article-title><source>DNA Repair (Amst)</source><year>2006</year><volume>5</volume><fpage>251</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">16309973</pub-id><pub-id pub-id-type="doi">10.1016/j.dnarep.2005.10.004</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bogdanova</surname><given-names>N</given-names></name><name><surname>Feshchenko</surname><given-names>S</given-names></name><name><surname>Schurmann</surname><given-names>P</given-names></name><name><surname>Waltes</surname><given-names>R</given-names></name><name><surname>Wieland</surname><given-names>B</given-names></name><name><surname>Hillemanns</surname><given-names>P</given-names></name><name><surname>Rogov</surname><given-names>YI</given-names></name><name><surname>Dammann</surname><given-names>O</given-names></name><name><surname>Bremer</surname><given-names>M</given-names></name><name><surname>Karstens</surname><given-names>JH</given-names></name><etal></etal></person-group><article-title>Nijmegen Breakage Syndrome mutations and risk of breast cancer</article-title><source>Int J Cancer</source><year>2008</year><volume>122</volume><fpage>802</fpage><lpage>806</lpage><pub-id pub-id-type="pmid">17957789</pub-id><pub-id pub-id-type="doi">10.1002/ijc.23168</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heikkinen</surname><given-names>K</given-names></name><name><surname>Rapakko</surname><given-names>K</given-names></name><name><surname>Karppinen</surname><given-names>SM</given-names></name><name><surname>Erkko</surname><given-names>H</given-names></name><name><surname>Knuutila</surname><given-names>S</given-names></name><name><surname>Lundan</surname><given-names>T</given-names></name><name><surname>Mannermaa</surname><given-names>A</given-names></name><name><surname>Borresen-Dale</surname><given-names>AL</given-names></name><name><surname>Borg</surname><given-names>A</given-names></name><name><surname>Barkardottir</surname><given-names>RB</given-names></name><etal></etal></person-group><article-title>RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability</article-title><source>Carcinogenesis</source><year>2006</year><volume>27</volume><fpage>1593</fpage><lpage>1599</lpage><pub-id pub-id-type="pmid">16474176</pub-id><pub-id pub-id-type="doi">10.1093/carcin/bgi360</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>HM</given-names></name><name><surname>Wang</surname><given-names>HC</given-names></name><name><surname>Chen</surname><given-names>ST</given-names></name><name><surname>Hsu</surname><given-names>GC</given-names></name><name><surname>Shen</surname><given-names>CY</given-names></name><name><surname>Yu</surname><given-names>JC</given-names></name></person-group><article-title>Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2007</year><volume>16</volume><fpage>2024</fpage><lpage>2032</lpage><pub-id pub-id-type="pmid">17932350</pub-id><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-07-0116</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nowak</surname><given-names>J</given-names></name><name><surname>Mosor</surname><given-names>M</given-names></name><name><surname>Ziolkowska</surname><given-names>I</given-names></name><name><surname>Wierzbicka</surname><given-names>M</given-names></name><name><surname>Pernak-Schwarz</surname><given-names>M</given-names></name><name><surname>Przyborska</surname><given-names>M</given-names></name><name><surname>Roznowski</surname><given-names>K</given-names></name><name><surname>Plawski</surname><given-names>A</given-names></name><name><surname>Slomski</surname><given-names>R</given-names></name><name><surname>Januszkiewicz</surname><given-names>D</given-names></name></person-group><article-title>Heterozygous carriers of the I171V mutation of the NBS1 gene have a significantly increased risk of solid malignant tumours</article-title><source>Eur J Cancer</source><year>2008</year><volume>44</volume><fpage>627</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">18280732</pub-id><pub-id pub-id-type="doi">10.1016/j.ejca.2008.01.006</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roznowski</surname><given-names>K</given-names></name><name><surname>Januszkiewicz-Lewandowska</surname><given-names>D</given-names></name><name><surname>Mosor</surname><given-names>M</given-names></name><name><surname>Pernak</surname><given-names>M</given-names></name><name><surname>Litwiniuk</surname><given-names>M</given-names></name><name><surname>Nowak</surname><given-names>J</given-names></name></person-group><article-title>I171V germline mutation in the NBS1 gene significantly increases risk of breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2008</year><volume>110</volume><fpage>343</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">17899368</pub-id><pub-id pub-id-type="doi">10.1007/s10549-007-9734-1</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seemanova</surname><given-names>E</given-names></name><name><surname>Jarolim</surname><given-names>P</given-names></name><name><surname>Seeman</surname><given-names>P</given-names></name><name><surname>Varon</surname><given-names>R</given-names></name><name><surname>Digweed</surname><given-names>M</given-names></name><name><surname>Swift</surname><given-names>M</given-names></name><name><surname>Sperling</surname><given-names>K</given-names></name></person-group><article-title>Cancer risk of heterozygotes with the NBN founder mutation</article-title><source>J Natl Cancer Inst</source><year>2007</year><volume>99</volume><fpage>1875</fpage><lpage>1880</lpage><pub-id pub-id-type="pmid">18073374</pub-id><pub-id pub-id-type="doi">10.1093/jnci/djm251</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Forsti</surname><given-names>A</given-names></name><name><surname>Angelini</surname><given-names>S</given-names></name><name><surname>Festa</surname><given-names>F</given-names></name><name><surname>Sanyal</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Grzybowska</surname><given-names>E</given-names></name><name><surname>Pamula</surname><given-names>J</given-names></name><name><surname>Pekala</surname><given-names>W</given-names></name><name><surname>Zientek</surname><given-names>H</given-names></name><name><surname>Hemminki</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Single nucleotide polymorphisms in breast cancer</article-title><source>Oncol Rep</source><year>2004</year><volume>11</volume><fpage>917</fpage><lpage>922</lpage><pub-id pub-id-type="pmid">15010895</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Millikan</surname><given-names>RC</given-names></name><name><surname>Player</surname><given-names>JS</given-names></name><name><surname>Decotret</surname><given-names>AR</given-names></name><name><surname>Tse</surname><given-names>CK</given-names></name><name><surname>Keku</surname><given-names>T</given-names></name></person-group><article-title>Polymorphisms in DNA repair genes, medical exposure to ionizing radiation, and breast cancer risk</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2005</year><volume>14</volume><fpage>2326</fpage><lpage>2334</lpage><pub-id pub-id-type="pmid">16214912</pub-id><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-05-0186</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dumon-Jones</surname><given-names>V</given-names></name><name><surname>Frappart</surname><given-names>PO</given-names></name><name><surname>Tong</surname><given-names>WM</given-names></name><name><surname>Sajithlal</surname><given-names>G</given-names></name><name><surname>Hulla</surname><given-names>W</given-names></name><name><surname>Schmid</surname><given-names>G</given-names></name><name><surname>Herceg</surname><given-names>Z</given-names></name><name><surname>Digweed</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>ZQ</given-names></name></person-group><article-title>Nbn heterozygosity renders mice susceptible to tumor formation and ionizing radiation-induced tumorigenesis</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>7263</fpage><lpage>7269</lpage><pub-id pub-id-type="pmid">14612522</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stumm</surname><given-names>M</given-names></name><name><surname>Neubauer</surname><given-names>S</given-names></name><name><surname>Keindorff</surname><given-names>S</given-names></name><name><surname>Wegner</surname><given-names>RD</given-names></name><name><surname>Wieacker</surname><given-names>P</given-names></name><name><surname>Sauer</surname><given-names>R</given-names></name></person-group><article-title>High frequency of spontaneous translocations revealed by FISH in cells from patients with the cancer-prone syndromes ataxia telangiectasia and Nijmegen breakage syndrome</article-title><source>Cytogenet Cell Genet</source><year>2001</year><volume>92</volume><fpage>186</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">11435685</pub-id><pub-id pub-id-type="doi">10.1159/000056900</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanzanella</surname><given-names>C</given-names></name><name><surname>Antoccia</surname><given-names>A</given-names></name><name><surname>Spadoni</surname><given-names>E</given-names></name><name><surname>di Masi</surname><given-names>A</given-names></name><name><surname>Pecile</surname><given-names>V</given-names></name><name><surname>Demori</surname><given-names>E</given-names></name><name><surname>Varon</surname><given-names>R</given-names></name><name><surname>Marseglia</surname><given-names>GL</given-names></name><name><surname>Tiepolo</surname><given-names>L</given-names></name><name><surname>Maraschio</surname><given-names>P</given-names></name></person-group><article-title>Chromosome instability and nibrin protein variants in NBS heterozygotes</article-title><source>Eur J Hum Genet</source><year>2003</year><volume>11</volume><fpage>297</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">12708449</pub-id><pub-id pub-id-type="doi">10.1038/sj.ejhg.5200962</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neubauer</surname><given-names>S</given-names></name><name><surname>Arutyunyan</surname><given-names>R</given-names></name><name><surname>Stumm</surname><given-names>M</given-names></name><name><surname>Dork</surname><given-names>T</given-names></name><name><surname>Bendix</surname><given-names>R</given-names></name><name><surname>Bremer</surname><given-names>M</given-names></name><name><surname>Varon</surname><given-names>R</given-names></name><name><surname>Sauer</surname><given-names>R</given-names></name><name><surname>Gebhart</surname><given-names>E</given-names></name></person-group><article-title>Radiosensitivity of ataxia telangiectasia and Nijmegen breakage syndrome homozygotes and heterozygotes as determined by three-color FISH chromosome painting</article-title><source>Radiat Res</source><year>2002</year><volume>157</volume><fpage>312</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">11839094</pub-id><pub-id pub-id-type="doi">10.1667/0033-7587(2002)157[0312:ROATAN]2.0.CO;2</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>DO</given-names></name><name><surname>Alt</surname><given-names>FW</given-names></name></person-group><article-title>DNA double strand break repair and chromosomal translocation: lessons from animal models</article-title><source>Oncogene</source><year>2001</year><volume>20</volume><fpage>5572</fpage><lpage>5579</lpage><pub-id pub-id-type="pmid">11607810</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1204767</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pierce</surname><given-names>AJ</given-names></name><name><surname>Stark</surname><given-names>JM</given-names></name><name><surname>Araujo</surname><given-names>FD</given-names></name><name><surname>Moynahan</surname><given-names>ME</given-names></name><name><surname>Berwick</surname><given-names>M</given-names></name><name><surname>Jasin</surname><given-names>M</given-names></name></person-group><article-title>Double-strand breaks and tumorigenesis</article-title><source>Trends Cell Biol</source><year>2001</year><volume>11</volume><fpage>S52</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">11684443</pub-id><pub-id pub-id-type="doi">10.1016/S0962-8924(01)02149-3</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fodde</surname><given-names>R</given-names></name><name><surname>Smits</surname><given-names>R</given-names></name></person-group><article-title>Cancer biology. A matter of dosage</article-title><source>Science</source><year>2002</year><volume>298</volume><fpage>761</fpage><lpage>763</lpage><pub-id pub-id-type="pmid">12399571</pub-id><pub-id pub-id-type="doi">10.1126/science.1077707</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simard</surname><given-names>J</given-names></name><name><surname>Dumont</surname><given-names>M</given-names></name><name><surname>Moisan</surname><given-names>AM</given-names></name><name><surname>Gaborieau</surname><given-names>V</given-names></name><name><surname>Malouin</surname><given-names>H</given-names></name><name><surname>Durocher</surname><given-names>F</given-names></name><name><surname>Chiquette</surname><given-names>J</given-names></name><name><surname>Plante</surname><given-names>M</given-names></name><name><surname>Avard</surname><given-names>D</given-names></name><name><surname>Bessette</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer</article-title><source>J Med Genet</source><year>2007</year><volume>44</volume><fpage>107</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">16905680</pub-id><pub-id pub-id-type="doi">10.1136/jmg.2006.044388</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Durocher</surname><given-names>F</given-names></name><name><surname>Labrie</surname><given-names>Y</given-names></name><name><surname>Soucy</surname><given-names>P</given-names></name><name><surname>Sinilnikova</surname><given-names>O</given-names></name><name><surname>Labuda</surname><given-names>D</given-names></name><name><surname>Bessette</surname><given-names>P</given-names></name><name><surname>Chiquette</surname><given-names>J</given-names></name><name><surname>Laframboise</surname><given-names>R</given-names></name><name><surname>Lepine</surname><given-names>J</given-names></name><name><surname>Lesperance</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families</article-title><source>BMC Cancer</source><year>2006</year><volume>6</volume><fpage>230</fpage><pub-id pub-id-type="pmid">17010193</pub-id><pub-id pub-id-type="doi">10.1186/1471-2407-6-230</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cartegni</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>MQ</given-names></name><name><surname>Krainer</surname><given-names>AR</given-names></name></person-group><article-title>ESEfinder: A web resource to identify exonic splicing enhancers</article-title><source>Nucleic Acids Res</source><year>2003</year><volume>31</volume><fpage>3568</fpage><lpage>3571</lpage><pub-id pub-id-type="pmid">12824367</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkg616</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reese</surname><given-names>MG</given-names></name><name><surname>Eeckman</surname><given-names>FH</given-names></name><name><surname>Kulp</surname><given-names>D</given-names></name><name><surname>Haussler</surname><given-names>D</given-names></name></person-group><article-title>Improved splice site detection in Genie</article-title><source>J Comput Biol</source><year>1997</year><volume>4</volume><fpage>311</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">9278062</pub-id><pub-id pub-id-type="doi">10.1089/cmb.1997.4.311</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>MB</given-names></name><name><surname>Senapathy</surname><given-names>P</given-names></name></person-group><article-title>RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression</article-title><source>Nucleic Acids Res</source><year>1987</year><volume>15</volume><fpage>7155</fpage><lpage>7174</lpage><pub-id pub-id-type="pmid">3658675</pub-id><pub-id pub-id-type="doi">10.1093/nar/15.17.7155</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guenard</surname><given-names>F</given-names></name><name><surname>Labrie</surname><given-names>Y</given-names></name><name><surname>Ouellette</surname><given-names>G</given-names></name><name><surname>Joly Beauparlant</surname><given-names>C</given-names></name><name><surname>Simard</surname><given-names>J</given-names></name><name><surname>Durocher</surname><given-names>F</given-names></name></person-group><article-title>Mutational analysis of the breast cancer susceptibility gene BRIP1/BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families</article-title><source>J Hum Genet</source><year>2008</year><volume>53</volume><fpage>579</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">18414782</pub-id><pub-id pub-id-type="doi">10.1007/s10038-008-0285-z</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Purcell</surname><given-names>S</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Sham</surname><given-names>PC</given-names></name></person-group><article-title>WHAP: haplotype-based association analysis</article-title><source>Bioinformatics</source><year>2007</year><volume>23</volume><fpage>255</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">17118959</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btl580</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ivanga</surname><given-names>M</given-names></name><name><surname>Labrie</surname><given-names>Y</given-names></name><name><surname>Calvo</surname><given-names>E</given-names></name><name><surname>Belleau</surname><given-names>P</given-names></name><name><surname>Martel</surname><given-names>C</given-names></name><name><surname>Pelletier</surname><given-names>G</given-names></name><name><surname>Morissette</surname><given-names>J</given-names></name><name><surname>Labrie</surname><given-names>F</given-names></name><name><surname>Durocher</surname><given-names>F</given-names></name></person-group><article-title>Fine temporal analysis of DHT transcriptional modulation of the ATM/Gadd45g signaling pathways in the mouse uterus</article-title><source>Mol Reprod Dev</source><year>2009</year><volume>76</volume><fpage>278</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">18671277</pub-id><pub-id pub-id-type="doi">10.1002/mrd.20949</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takai</surname><given-names>K</given-names></name><name><surname>Sakamoto</surname><given-names>S</given-names></name><name><surname>Sakai</surname><given-names>T</given-names></name><name><surname>Yasunaga</surname><given-names>J</given-names></name><name><surname>Komatsu</surname><given-names>K</given-names></name><name><surname>Matsuoka</surname><given-names>M</given-names></name></person-group><article-title>A potential link between alternative splicing of the NBS1 gene and DNA damage/environmental stress</article-title><source>Radiat Res</source><year>2008</year><volume>170</volume><fpage>33</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">18582154</pub-id><pub-id pub-id-type="doi">10.1667/RR1191.1</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Varon</surname><given-names>R</given-names></name><name><surname>Dutrannoy</surname><given-names>V</given-names></name><name><surname>Weikert</surname><given-names>G</given-names></name><name><surname>Tanzarella</surname><given-names>C</given-names></name><name><surname>Antoccia</surname><given-names>A</given-names></name><name><surname>Stockl</surname><given-names>L</given-names></name><name><surname>Spadoni</surname><given-names>E</given-names></name><name><surname>Kruger</surname><given-names>LA</given-names></name><name><surname>di Masi</surname><given-names>A</given-names></name><name><surname>Sperling</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Mild Nijmegen breakage syndrome phenotype due to alternative splicing</article-title><source>Hum Mol Genet</source><year>2006</year><volume>15</volume><fpage>679</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">16415040</pub-id><pub-id pub-id-type="doi">10.1093/hmg/ddi482</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>VG</given-names></name><name><surname>Ewens</surname><given-names>WJ</given-names></name></person-group><article-title>Heterozygous carriers of Nijmegen Breakage Syndrome have a distinct gene expression phenotype</article-title><source>Genome Res</source><year>2006</year><volume>16</volume><fpage>973</fpage><lpage>979</lpage><pub-id pub-id-type="pmid">16809669</pub-id><pub-id pub-id-type="doi">10.1101/gr.5320706</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Someya</surname><given-names>M</given-names></name><name><surname>Sakata</surname><given-names>K</given-names></name><name><surname>Tauchi</surname><given-names>H</given-names></name><name><surname>Matsumoto</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>A</given-names></name><name><surname>Komatsu</surname><given-names>K</given-names></name><name><surname>Hareyama</surname><given-names>M</given-names></name></person-group><article-title>Association of ionizing radiation-induced foci of NBS1 with chromosomal instability and breast cancer susceptibility</article-title><source>Radiat Res</source><year>2006</year><volume>166</volume><fpage>575</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">17007554</pub-id><pub-id pub-id-type="doi">10.1667/RR0638.1</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Antoniou</surname><given-names>AC</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name></person-group><article-title>Polygenic inheritance of breast cancer: Implications for design of association studies</article-title><source>Genet Epidemiol</source><year>2003</year><volume>25</volume><fpage>190</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">14557987</pub-id><pub-id pub-id-type="doi">10.1002/gepi.10261</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>di Masi</surname><given-names>A</given-names></name><name><surname>Viganotti</surname><given-names>M</given-names></name><name><surname>Polticelli</surname><given-names>F</given-names></name><name><surname>Ascenzi</surname><given-names>P</given-names></name><name><surname>Tanzarella</surname><given-names>C</given-names></name><name><surname>Antoccia</surname><given-names>A</given-names></name></person-group><article-title>The R215W mutation in NBS1 impairs gamma-H2AX binding and affects DNA repair: molecular bases for the severe phenotype of 657del5/R215W Nijmegen breakage syndrome patients</article-title><source>Biochem Biophys Res Commun</source><year>2008</year><volume>369</volume><fpage>835</fpage><lpage>840</lpage><pub-id pub-id-type="pmid">18328813</pub-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2008.02.129</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>J</given-names></name><name><surname>Tauchi</surname><given-names>H</given-names></name><name><surname>Sakamoto</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>A</given-names></name><name><surname>Morishima</surname><given-names>K</given-names></name><name><surname>Matsuura</surname><given-names>S</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Tamai</surname><given-names>K</given-names></name><name><surname>Tanimoto</surname><given-names>K</given-names></name><name><surname>Komatsu</surname><given-names>K</given-names></name></person-group><article-title>NBS1 localizes to gamma-H2AX foci through interaction with the FHA/BRCT domain</article-title><source>Curr Biol</source><year>2002</year><volume>12</volume><fpage>1846</fpage><lpage>1851</lpage><pub-id pub-id-type="pmid">12419185</pub-id><pub-id pub-id-type="doi">10.1016/S0960-9822(02)01259-9</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Varon</surname><given-names>R</given-names></name><name><surname>Reis</surname><given-names>A</given-names></name><name><surname>Henze</surname><given-names>G</given-names></name><name><surname>von Einsiedel</surname><given-names>HG</given-names></name><name><surname>Sperling</surname><given-names>K</given-names></name><name><surname>Seeger</surname><given-names>K</given-names></name></person-group><article-title>Mutations in the Nijmegen Breakage Syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL)</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>3570</fpage><lpage>3572</lpage><pub-id pub-id-type="pmid">11325820</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mosor</surname><given-names>M</given-names></name><name><surname>Ziolkowska</surname><given-names>I</given-names></name><name><surname>Pernak-Schwarz</surname><given-names>M</given-names></name><name><surname>Januszkiewicz-Lewandowska</surname><given-names>D</given-names></name><name><surname>Nowak</surname><given-names>J</given-names></name></person-group><article-title>Association of the heterozygous germline I171V mutation of the NBS1 gene with childhood acute lymphoblastic leukemia</article-title><source>Leukemia</source><year>2006</year><volume>20</volume><fpage>1454</fpage><lpage>1456</lpage><pub-id pub-id-type="pmid">16810201</pub-id><pub-id pub-id-type="doi">10.1038/sj.leu.2404285</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ziolkowska</surname><given-names>I</given-names></name><name><surname>Mosor</surname><given-names>M</given-names></name><name><surname>Wierzbicka</surname><given-names>M</given-names></name><name><surname>Rydzanicz</surname><given-names>M</given-names></name><name><surname>Pernak-Schwarz</surname><given-names>M</given-names></name><name><surname>Nowak</surname><given-names>J</given-names></name></person-group><article-title>Increased risk of larynx cancer in heterozygous carriers of the I171V mutation of the NBS1 gene</article-title><source>Cancer Sci</source><year>2007</year><volume>98</volume><fpage>1701</fpage><lpage>1705</lpage><pub-id pub-id-type="pmid">17894553</pub-id><pub-id pub-id-type="doi">10.1111/j.1349-7006.2007.00594.x</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>H</given-names></name><name><surname>Shimizu</surname><given-names>K</given-names></name><name><surname>Mimaki</surname><given-names>S</given-names></name><name><surname>Sakiyama</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Shimasaki</surname><given-names>N</given-names></name><name><surname>Yokota</surname><given-names>J</given-names></name><name><surname>Nakachi</surname><given-names>K</given-names></name><name><surname>Ohta</surname><given-names>T</given-names></name><name><surname>Ohki</surname><given-names>M</given-names></name></person-group><article-title>First case of aplastic anemia in a Japanese child with a homozygous missense mutation in the NBS1 gene (I171V) associated with genomic instability</article-title><source>Hum Genet</source><year>2004</year><volume>115</volume><fpage>372</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">15338273</pub-id><pub-id pub-id-type="doi">10.1007/s00439-004-1155-1</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bogdanova</surname><given-names>N</given-names></name><name><surname>Schurmann</surname><given-names>P</given-names></name><name><surname>Waltes</surname><given-names>R</given-names></name><name><surname>Feshchenko</surname><given-names>S</given-names></name><name><surname>Zalutsky</surname><given-names>IV</given-names></name><name><surname>Bremer</surname><given-names>M</given-names></name><name><surname>Dork</surname><given-names>T</given-names></name></person-group><article-title>NBS1 variant I171V and breast cancer risk</article-title><source>Breast Cancer Res Treat</source><year>2008</year><volume>112</volume><fpage>75</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">18049891</pub-id><pub-id pub-id-type="doi">10.1007/s10549-007-9820-4</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seemanova</surname><given-names>E</given-names></name><name><surname>Sperling</surname><given-names>K</given-names></name><name><surname>Neitzel</surname><given-names>H</given-names></name><name><surname>Varon</surname><given-names>R</given-names></name><name><surname>Hadac</surname><given-names>J</given-names></name><name><surname>Butova</surname><given-names>O</given-names></name><name><surname>Schrock</surname><given-names>E</given-names></name><name><surname>Seeman</surname><given-names>P</given-names></name><name><surname>Digweed</surname><given-names>M</given-names></name></person-group><article-title>Nijmegen breakage syndrome (NBS) with neurological abnormalities and without chromosomal instability</article-title><source>J Med Genet</source><year>2006</year><volume>43</volume><fpage>218</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">16033915</pub-id><pub-id pub-id-type="doi">10.1136/jmg.2005.035287</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cerosaletti</surname><given-names>KM</given-names></name><name><surname>Morrison</surname><given-names>VA</given-names></name><name><surname>Sabath</surname><given-names>DE</given-names></name><name><surname>Willerford</surname><given-names>DM</given-names></name><name><surname>Concannon</surname><given-names>P</given-names></name></person-group><article-title>Mutations and molecular variants of the NBS1 gene in non-Hodgkin lymphoma</article-title><source>Genes Chromosomes Cancer</source><year>2002</year><volume>35</volume><fpage>282</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">12353271</pub-id><pub-id pub-id-type="doi">10.1002/gcc.10114</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hebbring</surname><given-names>SJ</given-names></name><name><surname>Fredriksson</surname><given-names>H</given-names></name><name><surname>White</surname><given-names>KA</given-names></name><name><surname>Maier</surname><given-names>C</given-names></name><name><surname>Ewing</surname><given-names>C</given-names></name><name><surname>McDonnell</surname><given-names>SK</given-names></name><name><surname>Jacobsen</surname><given-names>SJ</given-names></name><name><surname>Cerhan</surname><given-names>J</given-names></name><name><surname>Schaid</surname><given-names>DJ</given-names></name><name><surname>Ikonen</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2006</year><volume>15</volume><fpage>935</fpage><lpage>938</lpage><pub-id pub-id-type="pmid">16702373</pub-id><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-05-0910</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Figueroa</surname><given-names>JD</given-names></name><name><surname>Malats</surname><given-names>N</given-names></name><name><surname>Rothman</surname><given-names>N</given-names></name><name><surname>Real</surname><given-names>FX</given-names></name><name><surname>Silverman</surname><given-names>D</given-names></name><name><surname>Kogevinas</surname><given-names>M</given-names></name><name><surname>Chanock</surname><given-names>S</given-names></name><name><surname>Yeager</surname><given-names>M</given-names></name><name><surname>Welch</surname><given-names>R</given-names></name><name><surname>Dosemeci</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk</article-title><source>Carcinogenesis</source><year>2007</year><volume>28</volume><fpage>1788</fpage><lpage>1793</lpage><pub-id pub-id-type="pmid">17557904</pub-id><pub-id pub-id-type="doi">10.1093/carcin/bgm132</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thirumaran</surname><given-names>RK</given-names></name><name><surname>Bermejo</surname><given-names>JL</given-names></name><name><surname>Rudnai</surname><given-names>P</given-names></name><name><surname>Gurzau</surname><given-names>E</given-names></name><name><surname>Koppova</surname><given-names>K</given-names></name><name><surname>Goessler</surname><given-names>W</given-names></name><name><surname>Vahter</surname><given-names>M</given-names></name><name><surname>Leonardi</surname><given-names>GS</given-names></name><name><surname>Clemens</surname><given-names>F</given-names></name><name><surname>Fletcher</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Single nucleotide polymorphisms in DNA repair genes and basal cell carcinoma of skin</article-title><source>Carcinogenesis</source><year>2006</year><volume>27</volume><fpage>1676</fpage><lpage>1681</lpage><pub-id pub-id-type="pmid">16501254</pub-id><pub-id pub-id-type="doi">10.1093/carcin/bgi381</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vineis</surname><given-names>P</given-names></name><name><surname>Manuguerra</surname><given-names>M</given-names></name><name><surname>Kavvoura</surname><given-names>FK</given-names></name><name><surname>Guarrera</surname><given-names>S</given-names></name><name><surname>Allione</surname><given-names>A</given-names></name><name><surname>Rosa</surname><given-names>F</given-names></name><name><surname>Di Gregorio</surname><given-names>A</given-names></name><name><surname>Polidoro</surname><given-names>S</given-names></name><name><surname>Saletta</surname><given-names>F</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name><etal></etal></person-group><article-title>A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility</article-title><source>J Natl Cancer Inst</source><year>2009</year><volume>101</volume><fpage>24</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">19116388</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Musak</surname><given-names>L</given-names></name><name><surname>Soucek</surname><given-names>P</given-names></name><name><surname>Vodickova</surname><given-names>L</given-names></name><name><surname>Naccarati</surname><given-names>A</given-names></name><name><surname>Halasova</surname><given-names>E</given-names></name><name><surname>Polakova</surname><given-names>V</given-names></name><name><surname>Slyskova</surname><given-names>J</given-names></name><name><surname>Susova</surname><given-names>S</given-names></name><name><surname>Buchancova</surname><given-names>J</given-names></name><name><surname>Smerhovsky</surname><given-names>Z</given-names></name><etal></etal></person-group><article-title>Chromosomal aberrations in tire plant workers and interaction with polymorphisms of biotransformation and DNA repair genes</article-title><source>Mutat Res</source><year>2008</year><volume>641</volume><fpage>36</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">18394656</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>R</given-names></name><name><surname>An</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name></person-group><article-title>Functional analysis of the Myostatin gene promoter in sheep</article-title><source>Sci China C Life Sci</source><year>2007</year><volume>50</volume><fpage>648</fpage><lpage>654</lpage><pub-id pub-id-type="pmid">17879064</pub-id><pub-id pub-id-type="doi">10.1007/s11427-007-0085-2</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>RJ</given-names></name><name><surname>Suh</surname><given-names>ER</given-names></name><name><surname>Lynch</surname><given-names>JP</given-names></name></person-group><article-title>The role of Cdx proteins in intestinal development and cancer</article-title><source>Cancer Biol Ther</source><year>2004</year><volume>3</volume><fpage>593</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">15136761</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mogal</surname><given-names>AP</given-names></name><name><surname>Meer</surname><given-names>R van der</given-names></name><name><surname>Crooke</surname><given-names>PS</given-names></name><name><surname>Abdulkadir</surname><given-names>SA</given-names></name></person-group><article-title>Haploinsufficient prostate tumor suppression by Nkx3.1: a role for chromatin accessibility in dosage-sensitive gene regulation</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>25790</fpage><lpage>25800</lpage><pub-id pub-id-type="pmid">17602165</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M702438200</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morinaga</surname><given-names>T</given-names></name><name><surname>Yasuda</surname><given-names>H</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Higashio</surname><given-names>K</given-names></name><name><surname>Tamaoki</surname><given-names>T</given-names></name></person-group><article-title>A human alpha-fetoprotein enhancer-binding protein, ATBF1, contains four homeodomains and seventeen zinc fingers</article-title><source>Mol Cell Biol</source><year>1991</year><volume>11</volume><fpage>6041</fpage><lpage>6049</lpage><pub-id pub-id-type="pmid">1719379</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaspar</surname><given-names>P</given-names></name><name><surname>Dvorakova</surname><given-names>M</given-names></name><name><surname>Kralova</surname><given-names>J</given-names></name><name><surname>Pajer</surname><given-names>P</given-names></name><name><surname>Kozmik</surname><given-names>Z</given-names></name><name><surname>Dvorak</surname><given-names>M</given-names></name></person-group><article-title>Myb-interacting protein, ATBF1, represses transcriptional activity of Myb oncoprotein</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>14422</fpage><lpage>14428</lpage><pub-id pub-id-type="pmid">10318867</pub-id><pub-id pub-id-type="doi">10.1074/jbc.274.20.14422</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miura</surname><given-names>Y</given-names></name><name><surname>Kataoka</surname><given-names>H</given-names></name><name><surname>Joh</surname><given-names>T</given-names></name><name><surname>Tada</surname><given-names>T</given-names></name><name><surname>Asai</surname><given-names>K</given-names></name><name><surname>Nakanishi</surname><given-names>M</given-names></name><name><surname>Okada</surname><given-names>N</given-names></name><name><surname>Okada</surname><given-names>H</given-names></name></person-group><article-title>Susceptibility to killer T cells of gastric cancer cells enhanced by Mitomycin-C involves induction of ATBF1 and activation of p21 (Waf1/Cip1) promoter</article-title><source>Microbiol Immunol</source><year>2004</year><volume>48</volume><fpage>137</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">14978340</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Yamashita</surname><given-names>H</given-names></name><name><surname>Toyama</surname><given-names>T</given-names></name><name><surname>Sugiura</surname><given-names>H</given-names></name><name><surname>Ando</surname><given-names>Y</given-names></name><name><surname>Mita</surname><given-names>K</given-names></name><name><surname>Hamaguchi</surname><given-names>M</given-names></name><name><surname>Kawaguchi</surname><given-names>M</given-names></name><name><surname>Miura</surname><given-names>Y</given-names></name><name><surname>Iwase</surname><given-names>H</given-names></name></person-group><article-title>ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>193</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">15671546</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Otto</surname><given-names>KB</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Subramanian</surname><given-names>K</given-names></name><name><surname>Vertino</surname><given-names>PM</given-names></name><name><surname>Dong</surname><given-names>JT</given-names></name></person-group><article-title>Infrequent mutation of ATBF1 in human breast cancer</article-title><source>J Cancer Res Clin Oncol</source><year>2007</year><volume>133</volume><fpage>103</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">16932943</pub-id><pub-id pub-id-type="doi">10.1007/s00432-006-0148-y</pub-id></citation></ref></ref-list></back></article> 